Original Article
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
N Engl J Med 2005; 353:2148-2157November 17, 2005
- Abstract
Background
Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic guanosine monophosphate, thereby enhancing the cyclic guanosine monophosphate–mediated relaxation and growth inhibition of vascular smooth-muscle cells, including those in the lung.
Methods
In this double-blind, placebo-controlled study, we randomly assigned 278 patients with symptomatic pulmonary arterial hypertension (either idiopathic or associated with connective-tissue disease or with repaired congenital systemic-to-pulmonary shunts) to placebo or sildenafil (20, 40, or 80 mg) orally three times daily for 12 weeks. The primary end point was the change from baseline to week 12 in the distance walked in six minutes. The change in mean pulmonary-artery pressure and World Health Organization (WHO) functional class and the incidence of clinical worsening were also assessed, but the study was not powered to assess mortality. Patients completing the 12-week randomized study could enter a long-term extension study.
Results
The distance walked in six minutes increased from baseline in all sildenafil groups; the mean placebo-corrected treatment effects were 45 m (+13.0 percent), 46 m (+13.3 percent), and 50 m (+14.7 percent) for 20, 40, and 80 mg of sildenafil, respectively (P<0.001 for all comparisons). All sildenafil doses reduced the mean pulmonary-artery pressure (P=0.04, P=0.01, and P<0.001, respectively), improved the WHO functional class (P=0.003, P<0.001, and P<0.001, respectively), and were associated with side effects such as flushing, dyspepsia, and diarrhea. The incidence of clinical worsening did not differ significantly between the patients treated with sildenafil and those treated with placebo. Among the 222 patients completing one year of treatment with sildenafil monotherapy, the improvement from baseline at one year in the distance walked in six minutes was 51 m.
Conclusions
Sildenafil improves exercise capacity, WHO functional class, and hemodynamics in patients with symptomatic pulmonary arterial hypertension.
Media in This Article
Figure 1
Numbers of Patients Enrolled in the 12-Week Study and in the Long-Term Extension Study Who Underwent Screening and Randomization.Figure 2
Mean Changes from Baseline, with 95 Percent Confidence Intervals, in the Six-Minute Walking Distance at Week 12 in the Placebo and Sildenafil Groups.Article Activity
- Article
Pulmonary arterial hypertension is defined as a group of diseases characterized by a progressive increase in pulmonary vascular resistance, leading to right ventricular failure and premature death.1,2 Pathobiologic mechanisms of the disease include pulmonary endothelial dysfunction, which leads to impaired production of vasodilators, such as nitric oxide and prostacyclin, and overexpression of vasoconstrictors, such as endothelin-1.3,4 Treatment includes conventional agents (anticoagulants, diuretics, digoxin, and supplemental oxygen, as well as calcium-channel blockers in selected patients), vasodilators, and antiproliferative agents such as prostanoids and endothelin-receptor antagonists, which are targeted at abnormalities of endothelial function.5,6
Four agents are currently approved for the treatment of pulmonary arterial hypertension in the United States and Europe5: intravenous epoprostenol, the inhaled prostacyclin analogue iloprost, the subcutaneously and intravenously administered prostacyclin analogue treprostinil, and the oral endothelin-receptor antagonist bosentan. Although these drugs are efficacious, adverse effects in terms of safety, tolerability, drug delivery, or all of these factors occur with all of these agents.5,6 In addition, some medical therapy may fail in some patients in which case they may be considered for lung transplantation.7
Changes in nitric oxide pathways have been detected in patients with pulmonary arterial hypertension,8,9 and although inhaled nitric oxide is used for testing acute vasoreactivity,5,6 the long-term administration of this agent is cumbersome and requires a complex delivery system.10 The pulmonary vasodilating effects of nitric oxide11 are mediated through its second messenger, cyclic guanosine monophosphate (cGMP),12 which is rapidly degraded by phosphodiesterases. Phosphodiesterase type 5 is the predominant phosphodiesterase isoform in the lung that metabolizes cGMP,13 and it has been shown to be up-regulated in conditions associated with pulmonary hypertension.14,15 By selectively inhibiting phosphodiesterase type 5, sildenafil citrate (Revatio, Pfizer) promotes the accumulation of intracellular cGMP16 and thereby enhances nitric oxide–mediated vasodilatation; it may also have antiproliferative effects on pulmonary vascular smooth-muscle cells.17 Initial studies involving animal models,14,18-22 data from open-label, uncontrolled trials involving patients with pulmonary arterial hypertension,23-28 and a small randomized, controlled study involving patients with idiopathic pulmonary arterial hypertension29 suggest that sildenafil is beneficial in the treatment of pulmonary arterial hypertension. The objectives of our double-blind, placebo-controlled clinical trial were to assess the efficacy and tolerability of three doses of sildenafil — 20, 40, and 80 mg given orally three times daily — in patients with pulmonary arterial hypertension.
Methods
Selection of Patients
Patients were included if they had pulmonary arterial hypertension (idiopathic, associated with connective-tissue disease, or occurring after surgical repair of congenital systemic-to-pulmonary shunts that had been performed at least five years previously). Pulmonary arterial hypertension was defined as a mean pulmonary-artery pressure of 25 mm Hg or more and a pulmonary-capillary wedge pressure of 15 mm Hg or less at rest. Study medication was added to the patient's conventional therapy. Treatment with intravenous epoprostenol, oral bosentan, intravenous or inhaled iloprost, or subcutaneous treprostinil and supplementation with L-arginine were prohibited. Patients with a six-minute walking distance of less than 100 m or more than 450 m were excluded. Local institutional review boards or independent ethics committees approved the protocol, and written informed consent was obtained from all patients.
Study Design
The initial study was a 12-week, double-blind, placebo-controlled trial conducted in 53 centers in the United States, Mexico, South America, Europe, Asia, Australia, South Africa, and Israel between October 2002 and November 2003. A stratified central-randomization scheme was used to assign patients to four treatment groups — those receiving 20, 40, or 80 mg of sildenafil or placebo three times daily — in a 1:1:1:1 ratio. The randomization was stratified with respect to the baseline walking distance (<325 m or ≥325 m) and cause of pulmonary arterial hypertension. Patients randomly assigned to 80 mg of sildenafil three times daily received 40 mg of sildenafil three times daily for the first seven days before the dose was escalated to 80 mg; patients randomly assigned to the other three treatment groups underwent dummy dose escalation after seven days.
All patients who completed the 12-week, double-blind study were eligible to enter a long-term extension study. Patients originally assigned to the groups receiving placebo, 20 mg of sildenafil, and 40 mg of sildenafil received 40 mg of sildenafil for the first six weeks of the extension study, and the dose was then increased to 80 mg of sildenafil. Patients originally assigned to receive 80 mg of sildenafil continued to receive that dose in the extension study but underwent dummy dose escalation at week 6 to maintain the blinding.
Outcome Measures
The primary measure of efficacy was the change in exercise capacity, as measured by the total distance walked in six minutes, from baseline to week 12.30 Other measures of efficacy were the changes in mean pulmonary-artery pressure, score on the Borg scale of dyspnea (with 0 representing no dyspnea and 10 maximal dyspnea), World Health Organization (WHO) functional classification of pulmonary arterial hypertension (an adaptation of the New York Heart Association classification),31 and time from randomization to clinical worsening (defined as death, transplantation, hospitalization for pulmonary arterial hypertension, or initiation of additional therapies for pulmonary arterial hypertension, such as intravenous epoprostenol or oral bosentan). Physical examinations and laboratory tests were performed, and investigators recorded adverse events throughout both studies.
Statistical Analysis
The database was retained by the sponsor, but the investigators had access to the complete database. The statistical analysis was performed by a statistician who is an employee of the sponsoring company; it was reviewed and approved by one of the academic authors, at the University of Washington, Seattle. The authors assume full responsibility for the completeness and accuracy of the content of the manuscript.
The primary end point was evaluated with the use of a sequential step-down, closed testing procedure,32-34 in which the mean response in each group receiving sildenafil was compared with that in the placebo group. The group receiving the highest dose of sildenafil (80 mg) was tested first, followed by the groups receiving 40 mg and 20 mg, provided that a significant benefit had been observed with the prior higher dose. If no significant benefit was observed in relation to a particular dose, then no further comparisons among doses were made. All pairwise comparisons for the primary end point were carried out at the prespecified two-sided alpha level of 0.01 with the use of a two-sample t-test, stratified for baseline walking distance and for categories according to cause. Assuming that there was a treatment effect from sildenafil of 55 m, as compared with placebo, and a standard deviation of 75 m, a sample of 60 patients per treatment group would provide 90 percent power to detect this difference at the two-sided alpha level of 0.01. With the allowance of a withdrawal rate of 12.5 percent after randomization, 275 patients were required for randomization.
The same sequential step-down testing procedure was used for analysis of the secondary end points, with pairwise comparisons performed at the two-sided alpha level of 0.05. Mean pulmonary-artery pressure was analyzed with the use of a stratified t-test; the time to clinical worsening was analyzed with the use of a stratified log-rank test (data for patients with no documentation of clinical worsening were included in the analysis as censored observations); the score on the Borg scale of dyspnea was analyzed with the use of a stratified Wilcoxon's rank-sum test; and the change in the WHO functional class from baseline to week 12 was analyzed with the use of logistic regression.
Intention-to-treat analyses were performed for all variables. To be included in the intention-to-treat analysis for the primary end point, the Borg dyspnea score, and the mean pulmonary-artery pressure, a patient must have received the study drug and had both a baseline and at least one post-baseline measurement of the specific end point. To be included in the intention-to-treat analysis for time to clinical worsening, a patient must have received the study drug. Missing data for assessments at week 12 were imputed with the use of the last-observation-carried-forward method.
A sensitivity analysis was performed, which included patients who had not had a baseline walking test (the baseline walking distance was imputed with the use of results from the patients' screening walking test) and patients with no assessments of walking distance after baseline. In this analysis, for patients for whom no assessments had been performed after baseline, the six-minute walking distance at week 12 was set to the baseline result; for patients who had died, the distance at week 12 was set to 0; and for all other patients, either the distance at week 12 or the last assessment that had been performed was carried forward. A per-protocol population analysis was also conducted.
Results
A total of 278 patients were randomly assigned to receive placebo (70 patients) or sildenafil in doses of 20 mg (69 patients), 40 mg (68 patients), or 80 mg (71 patients) three times daily (Figure 1Figure 1
Numbers of Patients Enrolled in the 12-Week Study and in the Long-Term Extension Study Who Underwent Screening and Randomization.); 277 of the randomized patients took at least one dose of the study medication.Baseline Characteristics
Baseline characteristics of the patients were similar among all four treatment groups (Table 1Table 1
Baseline Characteristics of the Patients.). Idiopathic pulmonary arterial hypertension was the most frequent diagnosis, and the predominant WHO functional classifications at baseline were class II (39 percent of patients) and class III (58 percent).Exercise Capacity
An increase in the distance walked in six minutes was observed in all groups receiving sildenafil, as compared with placebo, at week 4, and this effect was maintained at weeks 8 and 12 (Figure 2Figure 2
Mean Changes from Baseline, with 95 Percent Confidence Intervals, in the Six-Minute Walking Distance at Week 12 in the Placebo and Sildenafil Groups.). The mean placebo-corrected treatment effects among 266 patients at week 12 were 45 m among those receiving 20 mg of sildenafil (99 percent confidence interval, 21 to 70; P<0.001), 46 m for those receiving 40 mg (99 percent confidence interval, 20 to 72; P<0.001), and 50 m for those receiving 80 mg (99 percent confidence interval, 23 to 77; P<0.001). The sensitivity analysis that was performed with the use of alternative imputation methods for missing data corroborated the main analysis: the mean placebo-corrected treatment effects among 277 patients at week 12 were 38 m for those receiving 20 mg of sildenafil (99 percent confidence interval, 12 to 64; P<0.001), 45 m for those receiving 40 mg (99 percent confidence interval, 21 to 70; P<0.001), and 42 m for those receiving 80 mg (99 percent confidence interval, 9 to 75; P<0.001). The results from the per-protocol population analysis also confirmed the main analysis (P<0.001 for all three comparisons).Treatment Effects According to Subgroups
The treatment effect on the primary end point in each group receiving sildenafil was descriptively assessed for subgroups of patients that were defined according to demographic features, disease characteristics, and baseline variables (Figure 3Figure 3
Effect of Treatment on the Six-Minute Walking Distance from Baseline to Week 12 in Patient Subgroups.). There was placebo-corrected improvement in the mean six-minute walking distance in all subgroups receiving sildenafil.Borg Dyspnea Score
The change from baseline in scores on the Borg dyspnea scale among the patients treated with sildenafil did not differ significantly from the change in the placebo group. The median Borg dyspnea score decreased (reflecting improvement) by 1 point among patients receiving 20 mg of sildenafil (95 percent confidence interval, –1 to 0), by 0 for those receiving 40 mg (95 percent confidence interval, –1 to 0), and by –1 for those receiving 80 mg (95 percent confidence interval, –1.5 to 0), as compared with placebo.
Hemodynamics
The patients receiving sildenafil had decreases from the baseline value in mean pulmonary-artery pressure and in pulmonary vascular resistance, as well as an increase in the cardiac index. These changes differed significantly from those among the patients receiving placebo (Table 2Table 2
Mean Change in Hemodynamic Variables from Baseline to Week 12.).Clinical Worsening
No statistically significant decrease in the time to clinical worsening or in the incidence of clinical worsening was observed with sildenafil as compared with placebo (Table 3Table 3
Incidence of Clinical Worsening and of the Most Frequent Adverse Events in the Placebo and Sildenafil Groups.). An exploratory analysis showed that the proportion of hospitalizations for worsening of pulmonary arterial hypertension was greater in the placebo group than in the combined sildenafil groups (P=0.02).WHO Functional Class
Data on the WHO functional class were available for 273 patients. After 12 weeks of double-blind treatment, the proportions of patients with an improvement of at least one functional class were 7 percent for those receiving placebo, 28 percent for those receiving 20 mg of sildenafil (placebo-corrected difference, 21 percent; 95 percent confidence interval, 9 to 33 percent; P=0.003), 36 percent for those receiving 40 mg (placebo-corrected difference, 29 percent; 95 percent confidence interval, 16 to 42 percent; P<0.001), and 42 percent for those receiving 80 mg (placebo-corrected difference, 35 percent; 95 percent confidence interval, 22 to 48 percent; P<0.001).
Long-Term Treatment
Of the 265 patients who completed the randomized 12-week study, 259 entered the long-term prospective extension study, and 6 declined enrollment (Figure 1). Patients who had been assigned to receive placebo and were then titrated up to 80 mg of sildenafil during the first 12 weeks of the extension study (58 patients) had a mean increase from baseline in the six-minute walking distance of 42 m (95 percent confidence interval, 27 to 57 m) at week 12 of the extension.
Of the 259 patients enrolled in the extension study, 15 withdrew and 14 died before completing 12 months of treatment. As of February 4, 2005, 230 patients had been treated with sildenafil for at least 12 months (median, 589 days; range, 400 to 844). Eight of the 230 patients received additional treatment (with prostanoids or endothelin-receptor antagonists) for pulmonary arterial hypertension. An exploratory analysis was performed on the 222 patients receiving sildenafil monotherapy after 1 year; after 12 weeks of treatment, the mean change from baseline in the six-minute walking distance was 48 m (95 percent confidence interval, 40 to 55); after 12 months, the mean change was 51 m (95 percent confidence interval, 41 to 60).
Safety
Most adverse events were mild to moderate in intensity for all treatment groups (Table 3). No clinically significant changes were seen in any laboratory variables evaluated. Forty-two patients reported 68 serious adverse events. However, only two serious adverse events — left ventricular dysfunction in one patient receiving 20 mg of sildenafil and postural hypotension in another patient receiving an initial dose of 40 mg of sildenafil — were considered by the investigators to be related to the study medication. The distribution and incidence of adverse events were similar among patients with different types of pulmonary arterial hypertension, and the median times of first occurrence were clustered within the first four to five weeks of treatment.
One patient in the placebo group died from right heart failure, and one in the group receiving 20 mg of sildenafil died from acute pulmonary embolism and urosepsis. Two patients in the group receiving 80 mg of sildenafil died, one from acute myocardial infarction and one from pneumonia while receiving 40 mg three times daily during the first seven days of the titration period. No death was judged by the investigators to be causally related to the study treatment. Eight patients withdrew from the randomized 12-week study: two because of protocol violations, two because of withdrawal of consent, and four because of side effects (decreased renal function, lower-leg edema, cardiac arrhythmias, and headache).
Discussion
In this multicenter, randomized, double-blind, placebo-controlled trial, sildenafil significantly improved exercise capacity, as assessed according to the six-minute walking test, in patients with pulmonary arterial hypertension, whether it was idiopathic or related to connective-tissue disease or surgical repair of congenital systemic-to-pulmonary shunts. Our findings show that there is a symptomatic benefit associated with the inhibition of phosphodiesterase type 5 in patients with pulmonary arterial hypertension. All subgroups that were assessed had an improvement in exercise capacity with sildenafil treatment, regardless of demographic or disease characteristics or other baseline variables. The study was not designed to assess mortality.
The six-minute walking test is an independent predictor of death in patients with idiopathic pulmonary arterial hypertension35 and has been used as the primary end point in most clinical trials involving patients with pulmonary arterial hypertension.5 The treatment-related increase in walking distance of 45 to 50 m observed in this study is similar to the increases observed with the use of intravenous epoprostenol (47 m),36 inhaled iloprost (36 m),37 and oral bosentan (44 m)38 and is higher than the increase seen with the use of subcutaneous treprostinil (16 m).39
It should be emphasized that most patients in the present study had pulmonary arterial hypertension of WHO class II or III, representing a less sick population than in the other studies. In those trials, the sickest patients (those with pulmonary arterial hypertension of WHO class III or IV) had the greatest improvement in the six-minute walking distance. The extension study suggests that the effect of sildenafil monotherapy on exercise capacity is maintained after one year of treatment. This open-label, prospective evaluation reinforces the clinical significance of the exercise improvements observed in the 12-week study.
Sildenafil also significantly improved cardiopulmonary hemodynamics at 12 weeks, as compared with changes at 12 weeks in the placebo group. The reductions in pulmonary-artery pressure and increases in cardiac index were similar to those observed with intravenous epoprostenol36 and oral bosentan38 in smaller studies. Hemodynamic variables are related to survival in patients with idiopathic pulmonary arterial hypertension,40 and the results of this study confirm the clinical relevance of the effects of sildenafil. It is not clear what mechanisms are involved in the hemodynamic improvements seen in patients with pulmonary arterial hypertension who have predominantly fixed pulmonary vascular obstructive lesions.3 It has been suggested that there is possible reverse remodeling of pulmonary vascular changes with both prostanoids and endothelin-receptor antagonists, on the basis of their antiproliferative properties,6 and this may also explain the effects seen with sildenafil.17
The incidence of clinical worsening was not significantly different in the patients treated with sildenafil than in those treated with placebo. However, the overall incidence of clinical worsening in this study was low and may be related to the sizable cohort of patients with pulmonary arterial hypertension of WHO functional class II (39 percent) and to the short duration of the study (12 weeks). In fact, in our study, the overall incidence of clinical worsening in the placebo group was 10 percent (Table 3) and was lower than that in the placebo group of the Bosentan Randomized Trial of Endothelin Antagonist Therapy (BREATHE-1) study.38 In addition, in the BREATHE-1 study, a statistically significant difference in the time to clinical worsening was observed after 16 weeks, not 12.38
With all doses of sildenafil, most adverse events were of mild to moderate severity, and there were no clinically significant changes in laboratory variables. Complex delivery systems, significant side effects, or both, are associated with intravenous epoprostenol (e.g., catheter-related infections, sepsis, and pump malfunctions),36 subcutaneous treprostinil (infusion-site pain),39 inhaled iloprost (multiple daily inhalations),37 and oral bosentan (abnormalities of hepatic function).38
There was no evidence of a dose–response relationship associated with the primary end point (exercise capacity) or with tolerability in the 12-week study. The reason for this phenomenon is not clear but may be related to the complete inhibition of phosphodiesterase type 5 with the lowest dose.
Limitations of the study include the exclusion of certain patient populations with pulmonary arterial hypertension, such as patients in whom the pulmonary arterial hypertension is associated with the human immunodeficiency virus, patients with portal hypertension, and those with hypertension that is associated with uncorrected congenital systemic-to-pulmonary shunts. Additional studies involving these subgroups of patients are needed.
In conclusion, this study demonstrates the efficacy and safety of sildenafil in the treatment of patients with symptomatic pulmonary arterial hypertension. Our assessment of efficacy was limited to exercise capacity and hemodynamic measures, and the study was not designed to address the important end point of mortality.
Supported by Pfizer Global Research and Development, Sandwich, Kent, United Kingdom.
Dr. Galiè reports having served on the advisory boards of Pfizer, Actelion, Schering, Encysive, Myogen, and Mondobiotech and having received lecture fees from Actelion and Schering and grant support from Pfizer, Actelion, Schering, Encysive, and Myogen. Dr. Ghofrani reports having served on the advisory boards of Pfizer, Actelion, Schering, and Altana Pharma and having received lecture fees from Pfizer, Actelion, Lung Rx, and Schering and grant support from Pfizer and the German Research Foundation. Dr. Torbicki reports having served on the advisory boards of Pfizer, Encysive, and Mondobiotech and having received lecture fees from Actelion, Schering, and Myogen and grant support from the Foundation for Polish Science. Dr. Barst reports having served on the advisory boards of Actelion, CoTherix, Encysive, INO Therapeutics, Pfizer, United Therapeutics, Myogen, and Medtronic and having received lecture fees from Pfizer, Actelion, CoTherix, Encysive, and INO Therapeutics and grant support from Pfizer, Myogen, United Therapeutics, Actelion, CoTherix, Encysive, INO Therapeutics, and Medtronic. Dr. Rubin reports having served on the advisory boards of Pfizer, Actelion, Myogen, United Therapeutics, CoTherix, and Mondobiotech; having received lecture fees from Actelion and grant support from the National Heart, Lung, and Blood Institute, Pfizer, Actelion, United Therapeutics, and Myogen; and having served as an expert witness in diet-drug litigation. Dr. Badesch reports having served on the advisory boards of Pfizer, Actelion, Myogen, United Therapeutics, CoTherix, and Encysive; having received lecture fees from Actelion and Encysive and grant support from Pfizer, Actelion, Myogen, Cotherix, and Encysive; and having served as an expert witness in diet-drug litigation. Dr. Fleming reports having served on the advisory board of Pfizer. Drs. Parpia and Burgess are employees of Pfizer and report having equity interest in Pfizer. Dr. Branzi reports having received grant support from Pfizer, Actelion, Schering, Encysive, and Myogen. Dr. Grimminger reports having served on the advisory boards of Pfizer and Altana Pharma, and having received lecture fees from Pfizer and Schering and grant support from Pfizer, Bayer, Altana Pharma, and the German Research Foundation. Dr. Kurzyna reports having served as a consultant for Pfizer and having received lecture fees from Myogen. Dr. Simonneau reports having served on the advisory boards of Pfizer, Actelion, Schering, and Encysive, and having received lecture fees from Pfizer, Actelion, Encysive, and Schering and grant support from Pfizer, Actelion, Schering, and Encysive.
Source Information
From the Institute of Cardiology, University of Bologna, Bologna, Italy (N.G., A.B.); University Hospital, Justus-Liebig-University, Giessen, Germany (H.A.G., F.G.); the Institute of Tuberculosis and Lung Disease, Warsaw, Poland (A.T., M.K.); Babies and Children's Hospital, Columbia Presbyterian Medical Center, New York (R.J.B.); the University of California at San Diego, La Jolla (L.J.R.); University of Colorado Health Sciences Center, Denver (D.B.); the University of Washington, Seattle (T.F.); Pfizer Global Research and Development, Sandwich, Kent, United Kingdom (T.P., G.B.); and Hôpital Antoine Béclère, Clamart, France (G.S.).
Address reprint requests to Dr. Galiè at the Institute of Cardiology, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy, or at n.galie@bo.nettuno.it.
- References
References
1
Simonneau G ,Galie N ,Rubin LJ , et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:Suppl 12:5S-12S
CrossRef | Web of Science | Medline2
Rubin LJ . Primary pulmonary hypertension. N Engl J Med 1997;336:111-117
Full Text | Web of Science | Medline3
Humbert M ,Morrell NW ,Archer SL , et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:Suppl 12:13S-24S
CrossRef | Web of Science | Medline4
Farber HW ,Loscalzo J . Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-1665
Full Text | Web of Science | Medline5
Galie N ,Seeger W ,Naeije R ,Simonneau G ,Rubin LJ . Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:Suppl 12:81S-88S
CrossRef | Web of Science | Medline6
Humbert M ,Sitbon O ,Simonneau G . Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436
Full Text | Web of Science | Medline7
Klepetko W ,Mayer E ,Sandoval J , et al. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:Suppl 12:73S-80S
CrossRef | Web of Science | Medline8
Giaid A ,Saleh D . Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-221
Full Text | Web of Science | Medline9
Ghofrani HA ,Pepke-Zaba J ,Barbera JA , et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:Suppl 12:68S-72S
CrossRef | Web of Science | Medline10
Channick RN ,Newhart JW ,Johnson FW , et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest 1996;109:1545-1549
CrossRef | Web of Science | Medline11
Pepke-Zaba J ,Higenbottam TW ,Dinh-Xuan AT ,Stone D ,Wallwork J . Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991;338:1173-1174
CrossRef | Web of Science | Medline12
Moncada S ,Higgs A . The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-2012
Full Text | Web of Science | Medline13
Rabe KF ,Tenor H ,Dent G ,Schudt C ,Nakashima M ,Magnussen H . Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994;266:L536-L543
Web of Science | Medline14
Cohen AH ,Hanson K ,Morris K , et al. Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest 1996;97:172-179
CrossRef | Web of Science | Medline15
Jernigan NL ,Resta TC . Chronic hypoxia attenuates cGMP-dependent pulmonary vasodilation. Am J Physiol Lung Cell Mol Physiol 2002;282:L1366-L1375
Web of Science | Medline16
Corbin JD ,Francis SH . Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999;274:13729-13732
CrossRef | Web of Science | Medline17
Tantini B ,Manes A ,Fiumana E , et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2005;100:131-138
CrossRef | Web of Science | Medline18
Ichinose F ,Erana-Garcia J ,Hromi J , et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 2001;29:1000-1005
CrossRef | Web of Science | Medline19
Zhao L ,Mason NA ,Morrell NW , et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001;104:424-428
CrossRef | Web of Science | Medline20
Michelakis ED . The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Fail Rev 2003;8:5-21
CrossRef | Web of Science | Medline21
Schermuly RT ,Kreisselmeier KP ,Ghofrani HA , et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:39-45
CrossRef | Web of Science | Medline22
Rondelet B ,Kerbaul F ,Van Beneden R , et al. Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy. Circulation 2004;110:2220-2225
CrossRef | Web of Science | Medline23
Wilkens H ,Guth A ,Konig J , et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-1222
CrossRef | Web of Science | Medline24
Michelakis E ,Tymchak W ,Lien D ,Webster L ,Hashimoto K ,Archer S . Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105:2398-2403
CrossRef | Web of Science | Medline25
Ghofrani HA ,Wiedemann R ,Rose F , et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515-522
Web of Science | Medline26
Bhatia S ,Frantz RP ,Severson CJ ,Durst LA ,McGoon MD . Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003;78:1207-1213
CrossRef | Web of Science | Medline27
Ghofrani HA ,Rose F ,Schermuly RT , et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42:158-164
CrossRef | Web of Science | Medline28
Lepore JJ ,Maroo A ,Pereira NL , et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002;90:677-680
CrossRef | Web of Science | Medline29
Sastry BK ,Narasimhan C ,Reddy NK ,Raju BS . Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004;43:1149-1153
CrossRef | Web of Science | Medline30
Guyatt GH ,Sullivan MJ ,Thompson PJ , et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919-923
Web of Science | Medline31
Barst RJ ,McGoon M ,Torbicki A , et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:Suppl 12:40S-47S
CrossRef | Web of Science | Medline32
Chi GYH . Multiple testings: multiple comparisons and multiple end points. Drug Inf J 1998;32:Suppl:1347S-1362S
Web of Science33
Ruberg SJ . Dose response studies. II. Analysis and interpretation. J Biopharm Stat 1995;5:15-42[Erratum, J Biopharm Stat 1996;6:375.]
CrossRef | Medline34
Bauer P ,Rohmel J ,Maurer W ,Hothorn L . Testing strategies in multi-dose experiments including active control. Stat Med 1998;17:2133-2146
CrossRef | Web of Science | Medline35
Miyamoto S ,Nagaya N ,Satoh T , et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-492
Web of Science | Medline36
Barst RJ ,Rubin LJ ,Long WA , et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-302
Full Text | Web of Science | Medline37
Olschewski H ,Simonneau G ,Galie N , et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-329
Full Text | Web of Science | Medline38
Rubin LJ ,Badesch DB ,Barst RJ , et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903[Erratum, N Engl J Med 2002;346:1258.]
Full Text | Web of Science | Medline39
Simonneau G ,Barst RJ ,Galie N , et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-804
Web of Science | Medline40
D'Alonzo GE ,Barst RJ ,Ayres SM , et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-349
Web of Science | Medline
- Citing Articles (442)
Citing Articles
1
Cécile Tissot, Maurice Beghetti. 2012. Pediatric Pulmonary Hypertension. , 730-752.
CrossRef2
Paulino A. Alvarez, Ariel K. Saad, Santiago Flagel, Octavio Mazzocchi, Manuel Vazquez Blanco. (2012) Leflunomide-Induced Pulmonary Hypertension in a Young Woman with Rheumatoid Arthritis: A Case Report. Cardiovascular Toxicology
CrossRef3
John G. Coghlan, Benjamin Schrieber. (2012) An Update on the Evaluation and Management of Pulmonary Hypertension in Scleroderma. Current Rheumatology Reports
CrossRef4
M. S. Kutuk, M. T. Ozgun, C. Batukan, B. Ozcelik, M. Basbug, A. Ozturk. (2012) Oral tadalafil reduces intra-abdominal adhesion reformation in rats. Human Reproduction
CrossRef5
Masrat Rashid, Mohammad Fahim, Anita Kotwani. (2012) Efficacy of tadalafil in chronic hypobaric hypoxia-induced pulmonary hypertension: possible mechanisms. Fundamental & Clinical Pharmacologyno-no
CrossRef6
Maurice Beghetti, Nazzareno Galiè, Damien Bonnet. (2012) Can “Inoperable” Congenital Heart Defects Become Operable in Patients with Pulmonary Arterial Hypertension? Dream or Reality?. Congenital Heart Diseaseno-no
CrossRef7
Roberto Badagliacca, Beatrice Pezzuto, Roberto Poscia, Massimo Mancone, Silvia Papa, Serena Marcon, Gabriele Valli, Gennaro Sardella, Fabio Ferrante, Carlo Iacoboni, Daniela Parola, Francesco Fedele, Carmine Dario Vizza. (2012) Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: The impact of late referral. The Journal of Heart and Lung Transplantation
CrossRef8
Dunbar Ivy. (2012) Advances in pediatric pulmonary arterial hypertension. Current Opinion in Cardiology1
CrossRef9
M. T. Gonçalves de Medeiros, R. B. Oliveira, A. A. Santos, D. M. Leopoldino, M. C. Oliveira Lima, R. Arrais Nobre, M. Â. Nobre e Souza. (2012) The effects of sildenafil on rectal sensitivity and tone in patients with the irritable bowel syndrome. Alimentary Pharmacology & Therapeuticsn/a-n/a
CrossRef10
Roderick W.C. Scherptong, Ivo R. Henkens, Gijs F.L. Kapel, Cees A. Swenne, Klaas W. van Kralingen, Menno V. Huisman, Annemie J.M. Schuerwegh, Jeroen J. Bax, Ernst E. vd Wall, Martin J. Schalij, Hubert W. Vliegen. (2012) Diagnosis and mortality prediction in pulmonary hypertension: The value of the electrocardiogram-derived ventricular gradient. Journal of Electrocardiology
CrossRef11
John M. Wryobeck, Melvyn Rubenfire. 2011. Pulmonary Arterial Hypertension: Psychosocial Implications and Treatment. , 88-98.
CrossRef12
Vallerie V. McLaughlin, Melinda Davis, William Cornwell. (2011) Pulmonary Arterial Hypertension. Current Problems in Cardiology 36:12, 461-517
CrossRef13
Naveen Garg, Nishant Tripathy, Nakul Sinha. (2011) Comparative efficacy of sildenafil in Eisenmenger's syndrome secondary to atrial septal defect versus ventricular septal defect: a cardiac catheterisation follow-up study. Cardiology in the Young 21:06, 631-638
CrossRef14
Mae M. Centeno. (2011) Pulmonary Arterial Hypertension. Critical Care Nursing Clinics of North America 23:4, 645-659
CrossRef15
H. Ardeschir Ghofrani, Oliver Distler, Felix Gerhardt, Matthias Gorenflo, Ekkehard Grünig, Walter E. Haefeli, Matthias Held, Marius M. Hoeper, Christian M. Kähler, Harald Kaemmerer, Hans Klose, Volker Köllner, Bruno Kopp, Siegrun Mebus, Andreas Meyer, Oliver Miera, David Pittrow, Gabriela Riemekasten, Stephan Rosenkranz, Dietmar Schranz, Robert Voswinckel, Horst Olschewski. (2011) Treatment of pulmonary arterial hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011. International Journal of Cardiology 154, S20-S33
CrossRef16
E. S. Hoendermis. (2011) Pulmonary arterial hypertension: an update. Netherlands Heart Journal
CrossRef17
Henrik ten Freyhaus, Daniel Dumitrescu, Eva Berghausen, Marius Vantler, Evren Caglayan, Stephan Rosenkranz. (2011) Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opinion on Investigational Drugs1-16
CrossRef18
Dursun Alehan, Işıl Yıldırım, Murat Şahin, Süheyla Özkutlu, Sema Özer, Tevfik Karagöz. (2011) Long-term inhaled iloprost use in children with pulmonary arterial hypertension. Cardiology in the Young1-8
CrossRef19
Valentina Mercurio, Guido Carlomagno, Serafino Fazio. (2011) Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: Case report and review of the literature. Heart & Lung: The Journal of Acute and Critical Care
CrossRef20
S. H. Abman. (2011) Pulmonary Vascular Disease and Bronchopulmonary Dysplasia: Evaluation and Treatment of Pulmonary Hypertension. NeoReviews 12:11, e645-e651
CrossRef21
K. Nakamura, M. Yamasaki, H. Ohta, N. Sasaki, M. Murakami, W. R. Bandula Kumara, M. Takiguchi. (2011) Effects of sildenafil citrate on five dogs with Eisenmenger’s syndrome. Journal of Small Animal Practice 52:11, 595-598
CrossRef22
Brian J. Potter, Michel White, Michel Carrier, Michel Pellerin, Philippe L. L'Allier, Guy B. Pelletier, Normand Racine, Anique Ducharme. (2011) Hemodynamic and Clinical Benefits Associated With Chronic Sildenafil Therapy in Advanced Heart Failure: Experience of the Montréal Heart Institute. Canadian Journal of Cardiology
CrossRef23
Daniel P. Judge, David A. Kass, W. Reid Thompson, Kathryn R. Wagner. (2011) Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy. American Journal Cardiovascular Drugs 11:5, 287-294
CrossRef24
Laura Brenner, Wendy K. Chung. 2011. Clinical and Molecular Genetic Features of Hereditary Pulmonary Arterial Hypertension. .
CrossRef25
Faris Azzouni, Khawla Abu samra. (2011) Are Phosphodiesterase Type 5 Inhibitors Associated with Vision-Threatening Adverse Events? A Critical Analysis and Review of the Literature. The Journal of Sexual Medicine 8:10, 2894-2903
CrossRef26
Matthew G.D. Bates, A.A. Roger Thompson, J. Kenneth Baillie, Andrew I. Sutherland, John B. Irving, Nikhil Hirani, David J. Webb. (2011) Sildenafil Citrate for the Prevention of High Altitude Hypoxic Pulmonary Hypertension: Double Blind, Randomized, Placebo-Controlled Trial. High Altitude Medicine & Biology 12:3, 207-214
CrossRef27
Benjamin D. Fox, Avi Shimony, David Langleben. (2011) Meta-Analysis of Monotherapy Versus Combination Therapy for Pulmonary Arterial Hypertension. The American Journal of Cardiology 108:8, 1177-1182
CrossRef28
Moritz Beck-Broichsitter, Christoph Schweiger, Thomas Schmehl, Tobias Gessler, Werner Seeger, Thomas Kissel. (2011) Characterization of novel spray-dried polymeric particles for controlled pulmonary drug delivery. Journal of Controlled Release
CrossRef29
Maria Klara Frey, Irene Lang. (2011) Pulmonale Hypertension. Wiener klinische Wochenschrift Education 6:3, 78-93
CrossRef30
Moritz Beck-Broichsitter, Pia Kleimann, Tobias Gessler, Werner Seeger, Thomas Kissel, Thomas Schmehl. (2011) Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb® Pro: Formulation aspects and nanoparticle stability to nebulization. International Journal of Pharmaceutics
CrossRef31
M Nyp, T Sandritter, N Poppinga, C Simon, W E Truog. (2011) Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits?. Journal of Perinatology
CrossRef32
I. Mark Olfert, Alexander Loeckinger, Benedikt Treml, Martin Faulhaber, Markus Flatz, Martin Burtscher, Susanne Truebsbach, Axel Kleinsasser. (2011) Sildenafil and Bosentan Improve Arterial Oxygenation During Acute Hypoxic Exercise: A Controlled Laboratory Trial. Wilderness & Environmental Medicine 22:3, 211-221
CrossRef33
Raymond L. Benza, Mardi Gomberg-Maitland, Robert Naeije, Carl P. Arneson, Irene M. Lang. (2011) Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. The Journal of Heart and Lung Transplantation 30:9, 982-989
CrossRef34
Moritz Beck-Broichsitter, Thomas Schmehl, Tobias Gessler, Werner Seeger, Thomas Kissel. (2011) Development of a biodegradable nanoparticle platform for sildenafil: Formulation optimization by factorial design analysis combined with application of charge-modified branched polyesters. Journal of Controlled Release
CrossRef35
Hyoung-Chul Oh, Young Koog Cheon, Young Deok Cho, Jae Hyuk Do. (2011) Use of udenafil is not associated with a reduction in post-ERCP pancreatitis: results of a randomized, placebo-controlled, multicenter trial. Gastrointestinal Endoscopy 74:3, 556-562
CrossRef36
Paolo Ciliberti, Alessandro Giardini. (2011) Impact of oral chronic administration of sildenafil in children and young adults after the Fontan operation. Future Cardiology 7:5, 609-612
CrossRef37
Richa Agarwal, Mardi Gomberg-Maitland. (2011) Current therapeutics and practical management strategies for pulmonary arterial hypertension. American Heart Journal 162:2, 201-213
CrossRef38
Soumya Chatterjee. (2011) Pulmonary Hypertension in Systemic Sclerosis. Seminars in Arthritis and Rheumatism 41:1, 19-37
CrossRef39
Wei-Jie Zeng, Xian-Ling Lu, Chang-Ming Xiong, Guang-Liang Shan, Zhi-Hong Liu, Xin-Hai Ni, Qing Gu, Zhi-Hui Zhao, Jian-Jun Li, Jian-Guo He, . (2011) The Efficacy and Safety of Sildenafil in Patients With Pulmonary Arterial Hypertension Associated With the Different Types of Congenital Heart Disease. Clinical Cardiology 34:8, 513-518
CrossRef40
Kengo F. Kusano. (2011) Treatment for pulmonary hypertension including lung transplantation. General Thoracic and Cardiovascular Surgery 59:8, 538-546
CrossRef41
Peter Oishi, Sanjeev A Datar, Jeffrey R Fineman. (2011) Pediatric pulmonary arterial hypertension: current and emerging therapeutic options. Expert Opinion on Pharmacotherapy 12:12, 1845-1864
CrossRef42
Johann Strumpher, Eric Jacobsohn. (2011) Pulmonary Hypertension and Right Ventricular Dysfunction: Physiology and Perioperative Management. Journal of Cardiothoracic and Vascular Anesthesia 25:4, 687-704
CrossRef43
Sally A. Arif, Henry Poon. (2011) Tadalafil: A Long-Acting Phosphodiesterase-5 Inhibitor for the Treatment of Pulmonary Arterial Hypertension. Clinical Therapeutics 33:8, 993-1004
CrossRef44
R. F. Machado, R. J. Barst, N. A. Yovetich, K. L. Hassell, G. J. Kato, V. R. Gordeuk, J. S. R. Gibbs, J. A. Little, D. E. Schraufnagel, L. Krishnamurti, R. E. Girgis, C. R. Morris, E. B. Rosenzweig, D. B. Badesch, S. Lanzkron, O. Onyekwere, O. L. Castro, V. Sachdev, M. A. Waclawiw, R. Woolson, J. C. Goldsmith, M. T. Gladwin, . (2011) Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 118:4, 855-864
CrossRef45
Adriana Pavelescu, Robert Naeije. (2011) Effects of epoprostenol and sildenafil on right ventricular function in hypoxic volunteers: a tissue Doppler imaging study. European Journal of Applied Physiology
CrossRef46
Dermot S. O'Callaghan, Laurent Savale, David Montani, Xavier Jaïs, Olivier Sitbon, Gérald Simonneau, Marc Humbert. (2011) Treatment of pulmonary arterial hypertension with targeted therapies. Nature Reviews Cardiology 8:9, 526-538
CrossRef47
Yannis Hara, Yassine Sassi, Christelle Guibert, Natacha Gambaryan, Peter Dorfmüller, Saadia Eddahibi, Anne-Marie Lompré, Marc Humbert, Jean-Sébastien Hulot. (2011) Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. Journal of Clinical Investigation 121:7, 2888-2897
CrossRef48
James R. Klinger, Ronald J. Oudiz, Rebecca Spence, Darrin Despain, Christopher Dufton. (2011) Long-Term Pulmonary Hemodynamic Effects of Ambrisentan in Pulmonary Arterial Hypertension. The American Journal of Cardiology 108:2, 302-307
CrossRef49
M. Canuet, E. Gomez, A. Chaouat. (2011) Maladies vasculaires pulmonaires. Revue des Maladies Respiratoires Actualités 3:6, 128-139
CrossRef50
Sanna P. Niinivehmas, Salla I. Virtanen, Jukka V. Lehtonen, Pekka A. Postila, Olli T. Pentikäinen. (2011) Comparison of Virtual High-Throughput Screening Methods for the Identification of Phosphodiesterase-5 Inhibitors. Journal of Chemical Information and Modeling 51:6, 1353-1363
CrossRef51
Matthew T. Wheeler, Roham T. Zamanian. 2011. Pulmonary Hypertension and Right Heart Failure. , 81-93.
CrossRef52
Johanna Weiss, Melanie Herzog, Walter Emil Haefeli. (2011) Differential modulation of the expression of important drug metabolising enzymes and transporters by endothelin-1 receptor antagonists ambrisentan and bosentan in vitro. European Journal of Pharmacology 660:2-3, 298-304
CrossRef53
J. Volkmann, D. Muller, C. Feuerstacke, S. Kliesch, M. Bergmann, C. Muhlfeld, R. Middendorff. (2011) Disturbed spermatogenesis associated with thickened lamina propria of seminiferous tubules is not caused by dedifferentiation of myofibroblasts. Human Reproduction 26:6, 1450-1461
CrossRef54
Paul A. Corris. (2011) Alternatives to Lung Transplantation: Treatment of Pulmonary Arterial Hypertension. Clinics in Chest Medicine 32:2, 399-410
CrossRef55
Geoff Strange, Anne Keogh, Brad Dalton, Eli Gabbay. (2011) Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension. Expert Review of Pharmacoeconomics & Outcomes Research 11:3, 253-263
CrossRef56
Robyn J. Barst, Ronald J. Oudiz, Anthony Beardsworth, Bruce H. Brundage, Gerald Simonneau, Hossein A. Ghofrani, David P. Sundin, Nazzareno Galiè. (2011) Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. The Journal of Heart and Lung Transplantation 30:6, 632-643
CrossRef57
Tamera J. Corte, Theresa A. McDonagh, Stephen J. Wort. (2011) Pulmonary hypertension in left heart disease: A review. International Journal of Cardiology
CrossRef58
James L Lordan, Paul A Corris. (2011) Pulmonary arterial hypertension and lung transplantation. Expert Review of Respiratory Medicine 5:3, 441-454
CrossRef59
James R Klinger. (2011) Tadalafil for the treatment of pulmonary arterial hypertension. Expert Review of Respiratory Medicine 5:3, 315-328
CrossRef60
André P. Lourenço, Dulce Fontoura, Tiago Henriques-Coelho, Adelino F. Leite-Moreira. (2011) Current pathophysiological concepts and management of pulmonary hypertension. International Journal of Cardiology
CrossRef61
Reshma S Baliga, Raymond J MacAllister, Adrian J Hobbs. (2011) New perspectives for the treatment of pulmonary hypertension. British Journal of Pharmacology 163:1, 125-140
CrossRef62
M. A. Gebska, B. K. Stevenson, A. R. Hemnes, T. J. Bivalacqua, A. Haile, G. G. Hesketh, C. I. Murray, A. L. Zaiman, M. K. Halushka, N. Krongkaew, T. D. Strong, C. A. Cooke, H. El-Haddad, R. M. Tuder, D. E. Berkowitz, H. C. Champion. (2011) Phosphodiesterase-5A (PDE5A) is localized to the endothelial caveolae and modulates NOS3 activity. Cardiovascular Research 90:2, 353-363
CrossRef63
George F Lasker, Jason H Maley, Edward A Pankey, Philip J Kadowitz. (2011) Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension. Expert Review of Respiratory Medicine 5:2, 153-161
CrossRef64
Hanish Bagga, Karen S.W. Chia, Diane Freeman, Lyn Hales, David S. Henderson, Eugene Kotlyar, David Law, Pradeen Mudholkar, Cheryl Tulk, Jon H. Waites, Peter K.K. Wong. (2011) The initial 18 months of the first multi-disciplinary regional Pulmonary Arterial Hypertension Clinic in Australia. Australian Journal of Rural Health 19:2, 89-94
CrossRef65
Stefania Cicalini, Pierangelo Chinello, Nicola Petrosillo. (2011) HIV infection and pulmonary arterial hypertension. Expert Review of Respiratory Medicine 5:2, 257-266
CrossRef66
Bhashkar Mukherjee, Luke Howard. (2011) Combination therapy in pulmonary arterial hypertension: do we have the right strategy?. Expert Review of Respiratory Medicine 5:2, 191-205
CrossRef67
Guy Hagan, Joanna Pepke-Zaba. (2011) Pulmonary hypertension, nitric oxide and nitric oxide-releasing compounds. Expert Review of Respiratory Medicine 5:2, 163-171
CrossRef68
Stephen C Mathai, Paul M Hassoun. (2011) Pulmonary arterial hypertension associated with systemic sclerosis. Expert Review of Respiratory Medicine 5:2, 267-279
CrossRef69
Ralph T Schermuly, Wiebke Janssen, Norbert Weissmann, Johannes-Peter Stasch, Friedrich Grimminger, Hossein Ardeschir Ghofrani. (2011) Riociguat for the treatment of pulmonary hypertension. Expert Opinion on Investigational Drugs567-576
CrossRef70
A. Keogh, G. Strange, E. Kotlyar, T. Williams, D. Kilpatrick, P. Macdonald, K. Brown, A. Pidoux, F. Kermeen, P. Steele, B. Dalton, E. Gabbay. (2011) Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. Internal Medicine Journal 41:3, 235-244
CrossRef71
Alain Fraisse, Ghazwan Butrous, Mary B. Taylor, Michael Oakes, Maria Dilleen, David L. Wessel. (2011) Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Intensive Care Medicine 37:3, 502-509
CrossRef72
Yoshihiro Kuno, Masayuki Iyoda, Takanori Shibata, Yuki Hirai, Tadao Akizawa. (2011) Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats. British Journal of Pharmacology 162:6, 1389-1400
CrossRef73
Mitchell S Buckley, Laura M Wicks, Robin L Staib, Anna K Kirejczyk, Andrew S Varker, Jamie J Gibson, Jeremy P Feldman. (2011) Pharmacokinetic evaluation of ambrisentan. Expert Opinion on Drug Metabolism & Toxicology 7:3, 371-380
CrossRef74
Mardi Gomberg-Maitland, Christopher Dufton, Ronald J. Oudiz, Raymond L. Benza. (2011) Compelling Evidence of Long-Term Outcomes in Pulmonary Arterial Hypertension?. Journal of the American College of Cardiology 57:9, 1053-1061
CrossRef75
Showshan Yang-Ting, Jamil Aboulhosn, Xing-Guo Sun, John S. Child, Kathy E. Sietsema. (2011) Effects of Pulmonary Vasodilator Therapy on Ventilatory Efficiency during Exercise in Adults with Eisenmenger Syndrome. Congenital Heart Disease 6:2, 139-146
CrossRef76
David M. Smadja, Laetitia Mauge, Pascale Gaussem, Clément d’Audigier, Dominique Israel-Biet, David S. Celermajer, Damien Bonnet, Marilyne Lévy. (2011) Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension. Angiogenesis 14:1, 17-27
CrossRef77
B. S. Zuckerbraun, P. George, M. T. Gladwin. (2011) Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling. Cardiovascular Research 89:3, 542-552
CrossRef78
Jean-Luc Vachiery, Sandrine Huez, Hunter Gillies, Gary Layton, Naoto Hayashi, Xiang Gao, Robert Naeije. (2011) Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. British Journal of Clinical Pharmacology 71:2, 289-292
CrossRef79
Sushma K Vance, Yutaka Imamura, K Bailey Freund. (2011) THE EFFECTS OF SILDENAFIL CITRATE ON CHOROIDAL THICKNESS AS DETERMINED BY ENHANCED DEPTH IMAGING OPTICAL COHERENCE TOMOGRAPHY. Retina 31:2, 332-335
CrossRef80
Ivan M. Robbins, Anna R. Hemnes, J. Simon Gibbs, Brian W. Christman, Luke Howard, Sharon Meehan, Ines Cabrita, Rochelle Gonzalez, Tracy Oyler, Lan Zhao, Rui-Hong Du, Lisa A. Mendes, Martin R. Wilkins. (2011) Safety of sapropterin dihydrochloride (6r–bh4) in patients with pulmonary hypertension. Experimental Lung Research 37:1, 26-34
CrossRef81
Jeanne Houtchens, Douglas Martin, James R. Klinger. (2011) Diagnosis and Management of Pulmonary Arterial Hypertension. Pulmonary Medicine 2011, 1-13
CrossRef82
Walid Habre, Gergely Albu, Tibor Z Janosi, Fabienne Fontao, Britta S von Ungern-Sternberg, Maurice Beghetti, Ferenc Petak. (2011) Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension. Respiratory Research 12:1, 58
CrossRef83
Manish Malik, Rahul Nagpal. (2011) Emerging role of sildenafil in neonatology. Indian Pediatrics 48:1, 11-13
CrossRef84
Yoshihiro Fukumoto, Hiroaki Shimokawa. (2011) Recent Progress in the Management of Pulmonary Hypertension. Circulation Journal 75:8, 1801-1810
CrossRef85
L. Savale, D. S. O’Callaghan, R. Magnier, J. Le Pavec, P. Hervé, X. Jaïs, A. Seferian, M. Humbert, G. Simonneau, O. Sitbon. (2011) Current management approaches to portopulmonary hypertension. International Journal of Clinical Practice 65, 11-18
CrossRef86
Tohru Satoh, Tsutomu Saji, Hiroshi Watanabe, Satoshi Ogawa, Kazuhiko Takehara, Nobuhiro Tanabe, Norikazu Yamada, Atsushi Yao, Katsumasa Miyaji, Norifumi Nakanishi, Yumiko Suzuki, Tadami Fujiwara, Takayuki Kuriyama. (2011) A Phase III, Multicenter, Collaborative, Open-Label Clinical Trial of Sildenafil in Japanese Patients With Pulmonary Arterial Hypertension. Circulation Journal 75:3, 677-682
CrossRef87
Ann J. Impens, Kristine Phillips, Elena Schiopu. (2011) PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers: Current Status of Clinical Trials. International Journal of Rheumatology 2011, 1-5
CrossRef88
Georgia Pitsiou, Despina Papakosta, Demosthenes Bouros. (2011) Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis: A Review. Respiration 82:3, 294-304
CrossRef89
Norifumi Nakanishi. (2011) 2009 ESC/ERS Pulmonary Hypertension Guidelines and Connective Tissue Disease. Allergology International 60:4, 419-424
CrossRef90
Changhwan Kim, Yong Bum Park. (2011) Pharmacotherapy for pulmonary arterial hypertension. Journal of the Korean Medical Association 54:12, 1299
CrossRef91
Yuanyuan Bai, Lan Sun, Shengshou Hu, Yingjie Wei. (2011) Combination Therapy in Pulmonary Arterial Hypertension: A Meta-Analysis. Cardiology 120:3, 157-165
CrossRef92
Satyan Lakshminrusimha, Vasanth H. Kumar. 2011. Diseases of Pulmonary Circulation. , 632-656.
CrossRef93
Sherif Afifi, Shahriar Shayan, Abbas Al-Qamari. (2010) Pulmonary Hypertension and Right Ventricular Function. International Anesthesiology Clinics 47:1, 97-120
CrossRef94
Friedrich Grimminger, Ralph T. Schermuly, Hossein A. Ghofrani. (2010) Targeting non-malignant disorders with tyrosine kinase inhibitors. Nature Reviews Drug Discovery 9:12, 956-970
CrossRef95
Zeenat Safdar. (2010) Targeted Oral Therapies in the Treatment of Pulmonary Arterial Hypertension. Clinical Drug Investigation 30:12, 811-826
CrossRef96
Yoshimitsu Shimomura, Masahiko Hara, Isamu Mizote, Yoshikazu Nakaoka, Hirokazu Tanaka, Yoshihiro Asano, Yasushi Sakata, Issei Komuro. (2010) Sildenafil and steroid therapy effectively improved POEMS syndrome-associated pulmonary arterial hypertension. International Journal of Hematology 92:5, 774-776
CrossRef97
M.T.R. Roofthooft, R.L.E. van Loon, R.M.F. Berger. (2010) Management of Pulmonary Arterial Hypertension in Children. Paediatric Respiratory Reviews 11:4, 240-245
CrossRef98
Xian-Ling Lu, Chang-Ming Xiong, Guang-Liang Shan, Xian-Yang Zhu, Bing-Xiang Wu, Guang-Hua Wu, Zhi-Hong Liu, Xin-Hai Ni, Xian-Sheng Cheng, Qing Gu, Zhi-Hu Zhao, Duan-Zhen Zhang, Wei-Min Li, Cheng Zhang, Hong-Yan Tian, Ya-Juan Guo, Tao Guo, Hong-Min Liu, Wei-Jun Zhang, Hong Gu, Shi-An Huang, Jian-Ying Chen, Wei-Feng Wu, Kai Huang, Jian-Jun Li, Jian-Guo He. (2010) Impact of Sildenafil Therapy on Pulmonary Arterial Hypertension in Adults with Congenital Heart Disease. Cardiovascular Therapeutics 28:6, 350-355
CrossRef99
Tamera J. CORTE, Michael A. GATZOULIS, Lisa PARFITT, Carl HARRIES, Athol U. WELLS, S. John WORT. (2010) The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. Respirology 15:8, 1226-1232
CrossRef100
Marco Guazzi, Ross Arena. (2010) Pulmonary hypertension with left-sided heart disease. Nature Reviews Cardiology 7:11, 648-659
CrossRef101
Meredith E Pugh, Anna R Hemnes. (2010) Pulmonary hypertension in women. Expert Review of Cardiovascular Therapy 8:11, 1549-1558
CrossRef102
Roland S Wu, Steven O Marx. (2010) The BK potassium channel in the vascular smooth muscle and kidney: α- and β-subunits. Kidney International 78:10, 963-974
CrossRef103
Stephen Y Chan, Joseph Loscalzo. 2010. Pulmonary Vascular Disease Related to Hemodynamic Stress in the Pulmonary Circulation. .
CrossRef104
Cecile Tissot, David Dunbar Ivy, Maurice Beghetti. (2010) Medical Therapy for Pediatric Pulmonary Arterial Hypertension. The Journal of Pediatrics 157:4, 528-532
CrossRef105
Silvia Bellando-Randone, Serena Guiducci, Marco Matucci-Cerinic. (2010) Patient subgroups and potential risk factors in systemic sclerosis: is there a possibility of an early diagnosis?. International Journal of Clinical Rheumatology 5:5, 555-564
CrossRef106
Konstantinos Hatzimouratidis. (2010) Avanafil: a new phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. Aging Health 6:5, 599-605
CrossRef107
Tuguang Kuang, Jun Wang, Baosen Pang, Xiuxia Huang, Elyssa D. Burg, Jason X.-J. Yuan, Chen Wang. (2010) Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats. Pulmonary Pharmacology & Therapeutics 23:5, 456-464
CrossRef108
Sevdalina Lambova, Ulf Müller-Ladner. (2010) Pulmonary arterial hypertension in systemic sclerosis. Autoimmunity Reviews 9:11, 761-770
CrossRef109
Oleg Pak, Wiebke Janssen, Hossein Ardeschir Ghofrani, Werner Seeger, Friedrich Grimminger, Ralph Theo Schermuly, Norbert Weissmann. (2010) Animal models of pulmonary hypertension: role in translational research. Drug Discovery Today: Disease Models 7:3-4, 89-97
CrossRef110
N. Galie, M. Palazzini, A. Manes. (2010) Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. European Heart Journal 31:17, 2080-2086
CrossRef111
Daniel Dumitrescu, Erland Erdmann, Stephan Rosenkranz. (2010) PDE5-Inhibitoren in der Behandlung der pulmonalen Hypertonie. Beeinflussung des NO-Signalweges. Pharmazie in unserer Zeit 39:5, 391-396
CrossRef112
Amin Yehya, Teresa Lyle, Maria A. Pernetz, M.E. McConnell, B. Kogon, Wendy M. Book. (2010) Pulmonary arterial hypertension in patients with prior atrial switch procedure for d-transposition of great arteries (dTGA). International Journal of Cardiology 143:3, 271-275
CrossRef113
Alain Vuylsteke. 2010. Pulmonary Hypertension and Right Ventricular Failure. , 367-382.
CrossRef114
A.J. Brown, E. Davison, M.M. Sleeper. (2010) Clinical Efficacy of Sildenafil in Treatment of Pulmonary Arterial Hypertension in Dogs. Journal of Veterinary Internal Medicine 24:4, 850-854
CrossRef115
Dermot S. O’Callaghan, Laurent Savale, Xavier Jaïs, Delphine Natali, David Montani, Marc Humbert, Gérald Simonneau, Olivier Sitbon. (2010) Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. Respiratory Medicine 104, S74-S80
CrossRef116
Deborah H. McCollister, Michelle Beutz, Vallerie McLaughlin, John Rumsfeld, Frederick A. Masoudi, Mark Tripputi, Thomas Yaeger, Philippe Weintraub, David B. Badesch. (2010) Depressive Symptoms in Pulmonary Arterial Hypertension: Prevalence and Association With Functional Status. Psychosomatics 51:4, 339-339.e8
CrossRef117
John Granton. (2010) Outcomes in pulmonary hypertension: Beyond 40 metres. Canadian Journal of Cardiology 26, 12B-16B
CrossRef118
Silvio A. Ñamendys-Silva, Marisol Hernández-Garay, Eduardo Rivero-Sigarroa. (2010) Should we administer sildenafil to patients with acute respiratory distress syndrome? No. Intensive Care Medicine 36:6, 1102-1103
CrossRef119
Alexander D. Cornet, Nicole P. Juffermans. (2010) There is no place (yet) for routine administration of sildenafil to patients with ARDS. Intensive Care Medicine 36:6, 1104-1105
CrossRef120
Richard N. Channick. (2010) Pulmonary hypertension: Classification and treatment. Canadian Journal of Cardiology 26, 5B-11B
CrossRef121
M.M. Hoeper, H.A. Ghofrani, M. Gorenflo, E. Grünig, S. Rosenkranz, D. Schranz. (2010) Diagnostik und Therapie der pulmonalen Hypertonie. Der Kardiologe 4:3, 189-207
CrossRef122
Dimitar Sajkov, Nikolai Petrovsky, Paolo Palange. (2010) Management of dyspnea in advanced pulmonary arterial hypertension. Current Opinion in Supportive and Palliative Care 4:2, 76-84
CrossRef123
Nazzareno Galiè, Massimiliano Palazzini, Enri Leci, Alessandra Manes. (2010) Estrategias terapéuticas actuales en la hipertensión arterial pulmonar. Revista Española de Cardiología 63:6, 708-724
CrossRef124
Lewis Rubin, Gérald Simonneau. (2010) Perspective on the optimal endpoints for pulmonary arterial hypertension trials. Current Opinion in Pulmonary Medicine 16:Suppl 1, S43-S46
CrossRef125
J Gerry Coghlan, Janet Pope, Christopher P Denton. (2010) Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease. Current Opinion in Pulmonary Medicine 16:Suppl 1, S27-S34
CrossRef126
Horst Olschewski, Marius M. Hoeper, Juergen Behr, Ralf Ewert, Andreas Meyer, Mathias M. Borst, Jörg Winkler, Michael Pfeifer, Heinrike Wilkens, Hossein Ardeschir Ghofrani, Sylvia Nikkho, Werner Seeger. (2010) Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respiratory Medicine 104:5, 731-740
CrossRef127
Padmanabha Shenoy, Vikas Agarwal. (2010) Phosphodiesterase inhibitors in the management of autoimmune disease. Autoimmunity Reviews 9:7, 511-515
CrossRef128
Joe R. Anderson, James J. Nawarskas. (2010) Pharmacotherapeutic Management of Pulmonary Arterial Hypertension. Cardiology in Review 18:3, 148-162
CrossRef129
Alexander D. Cornet, Jorrit J. Hofstra, Eleonora L. Swart, Armand R. J. Girbes, Nicole P. Juffermans. (2010) Sildenafil attenuates pulmonary arterial pressure but does not improve oxygenation during ARDS. Intensive Care Medicine 36:5, 758-764
CrossRef130
Nazzareno Galiè, Gérald Simonneau, Robyn J Barst, David Badesch, Lewis Rubin. (2010) Clinical worsening in trials of pulmonary arterial hypertension: results and implications. Current Opinion in Pulmonary Medicine 16:Suppl 1, S11-S19
CrossRef131
Manuel Ramos-Casals, Vicent Fonollosa-Pla, Pilar Brito-Zerón, Antoni Sisó-Almirall. (2010) Targeted therapy for systemic sclerosis: how close are we?. Nature Reviews Rheumatology 6:5, 269-278
CrossRef132
K. Iversen, A. S. Jensen, T. V. Jensen, N. G. Vejlstrup, L. Sondergaard. (2010) Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. European Heart Journal 31:9, 1124-1131
CrossRef133
Jack Rychik, David Goldberg, Kathryn Dodds. (2010) Long-term results and consequences of single ventricle palliation. Progress in Pediatric Cardiology 29:1, 19-23
CrossRef134
Vallerie V. McLaughlin, Raymond L. Benza, Lewis J. Rubin, Richard N. Channick, Robert Voswinckel, Victor F. Tapson, Ivan M. Robbins, Horst Olschewski, Melvyn Rubenfire, Werner Seeger. (2010) Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 55:18, 1915-1922
CrossRef135
Andrew Peacock, Anne Keogh, Marc Humbert. (2010) Endpoints in pulmonary arterial hypertension: the role of clinical worsening. Current Opinion in Pulmonary Medicine 16:Suppl 1, S1-S9
CrossRef136
H.-A. Ghofrani, R. Voswinckel, F. Reichenberger, H. Gall, W. Seeger, F. Grimminger. (2010) Aktuelle Therapie der pulmonal-arteriellen Hypertonie. Der Pneumologe 7:3, 192-199
CrossRef137
Sheila G Haworth, Maurice Beghetti. (2010) Assessment of endpoints in the pediatric population: congenital heart disease and idiopathic pulmonary arterial hypertension. Current Opinion in Pulmonary Medicine 16:Suppl 1, S35-S41
CrossRef138
Glenda M. Ninkovich, Sally K. Miller, Patricia T. Alpert. (2010) Sickle-cell anemia and pulmonary hypertension. Journal of the American Academy of Nurse Practitioners 22:4, 198-204
CrossRef139
Gülten Taçoy, Numan Nadir Ekim, Atiye Çengel. (2010) Dramatic response of a patient with pregnancy induced idiopathic pulmonary arterial hypertension to sildenafil treatment. Journal of Obstetrics and Gynaecology Research 36:2, 414-417
CrossRef140
Rinat Kehat, Dean J. Bonsall, Robert North, Brenda Connors. (2010) Ocular findings of oral sildenafil use in term and near-term neonates. Journal of American Association for Pediatric Ophthalmology and Strabismus 14:2, 159-162
CrossRef141
Yee Wei Teo, Donna L Greenhalgh. (2010) Update on anaesthetic approach to pulmonary hypertension. European Journal of Anaesthesiology 27:4, 317-323
CrossRef142
Christian Apitz, Janette T. Reyes, Helen Holtby, Tilman Humpl, Andrew N. Redington. (2010) Pharmacokinetic and Hemodynamic Responses to Oral Sildenafil During Invasive Testing in Children With Pulmonary Hypertension. Journal of the American College of Cardiology 55:14, 1456-1462
CrossRef143
Mark S. Slaughter, Francis D. Pagani, Joseph G. Rogers, Leslie W. Miller, Benjamin Sun, Stuart D. Russell, Randall C. Starling, Leway Chen, Andrew J. Boyle, Suzanne Chillcott, Robert M. Adamson, Margaret S. Blood, Margarita T. Camacho, Katherine A. Idrissi, Michael Petty, Michael Sobieski, Susan Wright, Timothy J. Myers, David J. Farrar. (2010) Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. The Journal of Heart and Lung Transplantation 29:4, S1-S39
CrossRef144
Robert M. Jackson, Marilyn K. Glassberg, Carol F. Ramos, Pablo A. Bejarano, Ghazwan Butrous, Orlando Gómez-Marín. (2010) Sildenafil Therapy and Exercise Tolerance in Idiopathic Pulmonary Fibrosis. Lung 188:2, 115-123
CrossRef145
Mehdi Skhiri, Sharon A. Hunt, André Y. Denault, François Haddad. (2010) Tratamiento basado en la evidencia de la insuficiencia cardiaca derecha: una revisión sistemática de un campo empírico. Revista Española de Cardiología 63:4, 451-471
CrossRef146
Rudolf E. Stauber, Horst Olschewski. (2010) Portopulmonary hypertension: short review. European Journal of Gastroenterology & Hepatology 22:4, 385-390
CrossRef147
Teena Abraham, Gary Wu, Fabienne Vastey, Jonathan Rapp, Nasser Saad, Eric Balmir. (2010) Role of Combination Therapy in the Treatment of Pulmonary Arterial Hypertension. Pharmacotherapy 30:4, 390-404
CrossRef148
Candice K. Silversides, Omid Salehian, Erwin Oechslin, Markus Schwerzmann, Isabelle Vonder Muhll, Paul Khairy, Eric Horlick, Mike Landzberg, Folkert Meijboom, Carole Warnes, Judith Therrien. (2010) Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: Complex congenital cardiac lesions. Canadian Journal of Cardiology 26:3, e98-e117
CrossRef149
Avram Goldberg. (2010) Pulmonary Arterial Hypertension in Connective Tissue Diseases. Cardiology in Review 18:2, 85-88
CrossRef150
Alain Fraisse, David L. Wessel. (2010) Acute pulmonary hypertension in infants and children: cGMP-related drugs. Pediatric Critical Care Medicine 11, S37-S40
CrossRef151
Hossein-Ardeschir Ghofrani, Robert Voswinckel, Henning Gall, Ralph Schermuly, Norbert Weissmann, Werner Seeger, Friedrich Grimminger. (2010) Riociguat for pulmonary hypertension. Future Cardiology 6:2, 155-166
CrossRef152
Xiu-Zhen Sun, Zong-Fang Li, Yun Liu, Ping Fang, Man-Xiang Li. (2010) Inhibition of cGMP phosphodiesterase 5 suppresses matrix metalloproteinase-2 production in pulmonary artery smooth muscles cells. Clinical and Experimental Pharmacology and Physiology 37:3, 362-367
CrossRef153
Meredith E Pugh, Anna R Hemnes. (2010) Development of pulmonary arterial hypertension in women: interplay of sex hormones and pulmonary vascular disease. Women's Health 6:2, 285-296
CrossRef154
Isabel Blanco, Claudio Villaquirán, José Luis Valera, María Molina-Molina, Antoni Xaubet, Robert Rodríguez-Roisin, Joan A. Barberà, Josep Roca. (2010) Consumo máximo de oxígeno durante la prueba de marcha de 6 minutos en la enfermedad pulmonar intersticial difusa y en la hipertensión pulmonar. Archivos de Bronconeumología 46:3, 122-128
CrossRef155
Steven H. Abman. (2010) Pulmonary hypertension in children: A historical overview. Pediatric Critical Care Medicine 11, S4-S9
CrossRef156
Sheila G. Haworth. (2010) Idiopathic Pulmonary Arterial Hypertension in Childhood. Cardiology in Review 18:2, 64-66
CrossRef157
Warren D. Rosenblum. (2010) Pulmonary Arterial Hypertension. Cardiology in Review 18:2, 58-63
CrossRef158
D. Launay, O. Sitbon, J. Le Pavec, L. Savale, C. Tcherakian, A. Yaici, L. Achouh, F. Parent, X. Jais, G. Simonneau, M. Humbert. (2010) Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology 49:3, 490-500
CrossRef159
T. Schmeiser, U. Müller-Ladner. (2010) EULAR-Empfehlungen zur Behandlung der systemischen Sklerose. Zeitschrift für Rheumatologie 69:1, 87-92
CrossRef160
Alejandro Macchia, Roberto Marchioli, Gianni Tognoni, Marco Scarano, RosaMaria Marfisi, Luigi Tavazzi, Stuart Rich. (2010) Systematic review of trials using vasodilators in pulmonary arterial hypertension: Why a new approach is needed. American Heart Journal 159:2, 245-257
CrossRef161
Monnipa Suesaowalak, John P. Cleary, Anthony C. Chang. (2010) Advances in diagnosis and treatment of pulmonary arterial hypertension in neonates and children with congenital heart disease. World Journal of Pediatrics 6:1, 13-31
CrossRef162
TP Singh. (2010) Clinical use of sildenafil in pulmonary artery hypertension. Expert Review of Respiratory Medicine 4:1, 13-19
CrossRef163
Jagdish Hiremath, Sadagopa Thanikachalam, Keyur Parikh, Somasundaram Shanmugasundaram, Sudhakar Bangera, Leland Shapiro, Gregory B. Pott, Cindy L. Vnencak-Jones, Carl Arneson, Michael Wade, R. James White. (2010) Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-controlled trial. The Journal of Heart and Lung Transplantation 29:2, 137-149
CrossRef164
Mantej K Chhina, Weir Nargues, Geraldine M Grant, Steven D Nathan. (2010) Evaluation of imatinib mesylate in the treatment of pulmonary arterial hypertension. Future Cardiology 6:1, 19-35
CrossRef165
Hiroyuki Amano, Nobuhiro Tanabe, Seiichiro Sakao, Hideo Umekita, Toshihiko Sugiura, Satoru Kitazono, Miyako Kitazono, Fuminobu Kuroda, Yasunori Kasahara, Koichiro Tatsumi. (2010) A Case of Isolated Peripheral Pulmonary Artery Branch Stenosis Associated with Multiple Pulmonary Artery Aneurysms. Internal Medicine 49:17, 1895-1899
CrossRef166
Peter K. Wung, Fredrick M. Wigley. 2010. Management of Systemic Sclerosis and Raynaud's Phenomenon. , 157-165.
CrossRef167
Yutaka Miura, Yoshihiro Fukumoto, Koichiro Sugimura, Minako Oikawa, Makoto Nakano, Shunsuke Tatebe, Saori Miyamichi, Kimio Satoh, Hiroaki Shimokawa. (2010) Identification of New Prognostic Factors of Pulmonary Hypertension. Circulation Journal 74:9, 1965-1971
CrossRef168
Carl Carlino, Joseph D. Tobias, Rebecca I. Schneider, Randall L. Heller, Martin A. Alpert, Ryan E. Grueber, Kevin C. Dellsperger, Vincent G. Demarco. (2010) Pulmonary Hemodynamic Response to Acute Combination and Monotherapy With Sildenafil and Brain Natriuretic Peptide in Rats With Monocrotaline-Induced Pulmonary Hypertension. The American Journal of the Medical Sciences 339:1, 55-59
CrossRef169
Yoshihiko Seino. (2010) Role of sildenafil in the treatment of pulmonary hypertension. Nihon Shuchu Chiryo Igakukai zasshi 17:4, 462-464
CrossRef170
G.-P. Diller, H. Baumgartner. (2010) Pulmonary arterial hypertension in adults with congenital heart disease. International Journal of Clinical Practice 64, 13-24
CrossRef171
Sheila G. Haworth, Marlene Rabinovitch. 2010. Pulmonary Circulation. , 117-141.
CrossRef172
Tilman Humpl, Ingram Schulze-Neick. 2010. Pulmonary Vascular Disease. , 1147-1161.
CrossRef173
Dong Seok Lee, Yung Kyu Kim, Yong Wook Jung. (2010) Simvastatin, Sildenafil and Their Combination in Monocrotaline Induced Pulmonary Arterial Hypertension. Korean Circulation Journal 40:12, 659
CrossRef174
Bing He, Fengwen Zhang, Xueying Li, Chaoshu Tang, Guosheng Lin, Junbao Du, Hongfang Jin. (2010) Meta-Analysis of Randomized Controlled Trials on Treatment of Pulmonary Arterial Hypertension. Circulation Journal 74:7, 1458-1464
CrossRef175
F. Giuliano, G. Jackson, F. Montorsi, A. Martin-Morales, P. Raillard. (2010) Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. International Journal of Clinical Practice 64:2, 240-255
CrossRef176
Antonio Aversa, Roberto Bruzziches, Davide Francomano, Edoardo Rosato, Felice Salsano, Giovanni Spera. (2010) Penile involvement in Systemic Sclerosis: New Diagnostic and Therapeutic Aspects. International Journal of Rheumatology 2010, 1-5
CrossRef177
Tanveer A. Khan, Gabriel Schnickel, David Ross, Sam Bastani, Hillel Laks, Fardad Esmailian, Daniel Marelli, Ramin Beygui, Richard Shemin, Larry Watson, Irina Vartapetian, Abbas Ardehali. (2009) A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. The Journal of Thoracic and Cardiovascular Surgery 138:6, 1417-1424
CrossRef178
Sheng Chin Wu, Sergio Caravita, Elisabetta Lisi, Simona Pierini, Viola Dadone, Sarah E. Todd, Francesco Gentile, Maria Beatrice Secchi. (2009) Pulmonary arterial hypertension. Internal and Emergency Medicine 4:6, 459-470
CrossRef179
R. Krishna Kumar, Julio Sandoval. (2009) Advanced pulmonary vascular disease: the Eisenmenger syndrome. Cardiology in the Young 19:06, 622
CrossRef180
Matthew Movsesian, Josef Stehlik, Fabrice Vandeput, Michael R. Bristow. (2009) Phosphodiesterase inhibition in heart failure. Heart Failure Reviews 14:4, 255-263
CrossRef181
Nazzareno Galiè, Marius M. Hoeper, Marc Humbert, Adam Torbicki, Jean-Luc Vachiery, Joan Albert Barberá, Maurice Beghetti, Paul Corris, Sean Gaine, J. Simon Gibbs, Miguel Ángel Gómez-Sánchez, Guillaume Jondeau, Walter Klepetko, Christian Opitz, Andrew Peacock, Lewis Rubin, Michael Zellweger, Gerald Simonneau. (2009) Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. Revista Española de Cardiología 62:12, 1464.e1-1464.e58
CrossRef182
Robin H. Steinhorn, John P. Kinsella, Christine Pierce, Ghazwan Butrous, Maria Dilleen, Michael Oakes, David L. Wessel. (2009) Intravenous Sildenafil in the Treatment of Neonates with Persistent Pulmonary Hypertension. The Journal of Pediatrics 155:6, 841-847.e1
CrossRef183
Archer, Stephen L., Michelakis, Evangelos D., . (2009) Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension. New England Journal of Medicine 361:19, 1864-1871
Full Text184
Matt D. Stevenson, Frances C. Macdonald, Jonathan Langley, Elke Hunsche, Ron Akehurst. (2009) The Cost-Effectiveness of Bosentan in the United Kingdom for Patients with Pulmonary Arterial Hypertension of WHO Functional Class III. Value in Health 12:8, 1100-1105
CrossRef185
Ronald J. Oudiz, Nazzareno Galiè, Horst Olschewski, Fernando Torres, Adaani Frost, Hossein A. Ghofrani, David B. Badesch, Michael D. McGoon, Vallerie V. McLaughlin, Ellen B. Roecker, Brooke C. Harrison, Darrin Despain, Christopher Dufton, Lewis J. Rubin. (2009) Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 54:21, 1971-1981
CrossRef186
Zeenat Safdar. (2009) Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan. Respiratory Medicine 103:11, 1688-1692
CrossRef187
Stephen C Mathai, Paul M Hassoun. (2009) Therapy for pulmonary arterial hypertension associated with systemic sclerosis. Current Opinion in Rheumatology 21:6, 642-648
CrossRef188
, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, J. S. Gibbs, M. A. Gomez-Sanchez, G. Jondeau, W. Klepetko, C. Opitz, A. Peacock, L. Rubin, M. Zellweger, G. Simonneau, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, K. McGregor, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. Vardas, P. Widimsky, , U. Sechtem, N. Al Attar, F. Andreotti, M. Aschermann, R. Asteggiano, R. Benza, R. Berger, D. Bonnet, M. Delcroix, L. Howard, A. N. Kitsiou, I. Lang, A. Maggioni, J. E. Nielsen-Kudsk, M. Park, P. Perrone-Filardi, S. Price, M. T. S. Domenech, A. Vonk-Noordegraaf, J. L. Zamorano. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal 30:20, 2493-2537
CrossRef189
Xi-Qi Xu, Zhi-Cheng Jing, Jin-Hu Zhang, Yan Wu, Yong Wang, Xin Jiang, Zhi-Xing Wang, Yin-Guang Sun, Jie-Lin Pu, Yue-Jin Yang. (2009) The efficacy and safety of sildenafil in Chinese patients with pulmonary arterial hypertension. Hypertension Research 32:10, 911-915
CrossRef190
Sohita Dhillon, Gillian M. Keating. (2009) Bosentan. American Journal Cardiovascular Drugs 9:5, 331-350
CrossRef191
Alice J. Huddleston, Chad A. Knoderer, Jennifer L. Morris, Eric S. Ebenroth. (2009) Sildenafil for the Treatment of Pulmonary Hypertension in Pediatric Patients. Pediatric Cardiology 30:7, 871-882
CrossRef192
Margaret C. Garin, Leslie Clark, Elinor C.G. Chumney, Kit N. Simpson, Kristin B. Highland. (2009) Cost-Utility of Treatments for Pulmonary Arterial Hypertension. Clinical Drug Investigation 29:10, 635-646
CrossRef193
R. Voswinckel, F. Reichenberger, H. Gall, W. Seeger, F. Grimminger, H.A. Ghofrani. (2009) Therapie der pulmonalarteriellen Hypertonie. Der Internist 50:9, 1101-1110
CrossRef194
Geoff STRANGE, Peter NASH. (2009) The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy. International Journal of Rheumatic Diseases 12:3, 192-206
CrossRef195
David Montani, Marie-Camille Chaumais, Laurent Savale, Delphine Natali, Laura C. Price, Xavier Jaïs, Marc Humbert, Gérald Simonneau, Olivier Sitbon. (2009) Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Advances in Therapy 26:9, 813-825
CrossRef196
T. Rasekaba, A. L. Lee, M. T. Naughton, T. J. Williams, A. E. Holland. (2009) The six-minute walk test: a useful metric for the cardiopulmonary patient. Internal Medicine Journal 39:8, 495-501
CrossRef197
Sevil Korkmaz, Tamás Radovits, Enikő Barnucz, Philipp Neugebauer, Rawa Arif, Kristóf Hirschberg, Sivakkanan Loganathan, Beatrice Seidel, Matthias Karck, Gábor Szabó. (2009) Dose-dependent effects of a selective phosphodiesterase-5-inhibitor on endothelial dysfunction induced by peroxynitrite in rat aorta. European Journal of Pharmacology 615:1-3, 155-162
CrossRef198
Manuel López-Meseguer, Antonio Román, Víctor Monforte, Carlos Bravo, Joan Solé, Ferran Morell. (2009) Trasplante bipulmonar en hipertensión pulmonar. Una serie de 15 pacientes. Archivos de Bronconeumología 45:8, 366-370
CrossRef199
T.H. Chapman, M. Wilde, A. Sheth, B.P. Madden. (2009) Sildenafil therapy in secondary pulmonary hypertension: Is there benefit in prolonged use?. Vascular Pharmacology 51:2-3, 90-95
CrossRef200
Chao Liu, Junmin Chen, Yanqiu Gao, Bao Deng, Kunshen Liu, Chao Liu. 2009. Endothelin receptor antagonists for pulmonary arterial hypertension. .
CrossRef201
Nathan M Kerr, Helen V Danesh-Meyer. (2009) Phosphodiesterase inhibitors and the eye. Clinical & Experimental Ophthalmology 37:5, 514-523
CrossRef202
Alan W. Shindel. (2009) 2009 Update on Phosphodiesterase Type 5 Inhibitor Therapy Part 1: Recent Studies on Routine Dosing for Penile Rehabilitation, Lower Urinary Tract Symptoms, and Other Indications (CME). Journal of Sexual Medicine 6:7, 1794-1808
CrossRef203
Shinichi Toyooka, Kengo Fukushima Kusano, Keiji Goto, Yamane Masaomi, Takahiro Oto, Yoshifumi Sano, Soichiro Fuke, Megumi Okazaki, Toru Ohe, Shingo Kasahara, Shunji Sano, Hiroshi Date. (2009) Right but not left ventricular function recovers early after living-donor lobar lung transplantation in patients with pulmonary arterial hypertension. The Journal of Thoracic and Cardiovascular Surgery 138:1, 222-226
CrossRef204
Arnon Blum. (2009) Treating Heart Failure With Sildenafil. Congestive Heart Failure 15:4, 181-185
CrossRef205
Eiki Takimoto, David A Kass. (2009) Sildenafil’s protective effect against cardiac hypertrophy. Expert Review of Clinical Pharmacology 2:4, 323-327
CrossRef206
V. McLaughlin, M. Humbert, G. Coghlan, P. Nash, V. Steen. (2009) Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology 48:Supplement 3, iii25-iii31
CrossRef207
C. F. Opitz, W. Kirch, E. A. Mueller, D. Pittrow. (2009) Bleeding events in pulmonary arterial hypertension. European Journal of Clinical Investigation 39, 68-73
CrossRef208
S. S. Pullamsetti, R. T. Schermuly. (2009) Endothelin receptor antagonists in preclinical models of pulmonary hypertension. European Journal of Clinical Investigation 39, 3-13
CrossRef209
Christopher I. Zoumalan, Roham T. Zamanian, Ramona L. Doyle, Michael F. Marmor. (2009) ERG evaluation of daily, high-dose sildenafil usage. Documenta Ophthalmologica 118:3, 225-231
CrossRef210
David B. Badesch, Hunter C. Champion, Miguel Angel Gomez Sanchez, Marius M. Hoeper, James E. Loyd, Alessandra Manes, Michael McGoon, Robert Naeije, Horst Olschewski, Ronald J. Oudiz, Adam Torbicki. (2009) Diagnosis and Assessment of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 54:1, S55-S66
CrossRef211
Robyn J. Barst, J. Simon R. Gibbs, Hossein A. Ghofrani, Marius M. Hoeper, Vallerie V. McLaughlin, Lewis J. Rubin, Olivier Sitbon, Victor F. Tapson, Nazzareno Galiè. (2009) Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 54:1, S78-S84
CrossRef212
Cecile Tissot, Maurice Beghetti. (2009) Advances in therapies for pediatric pulmonary arterial hypertension. Expert Review of Respiratory Medicine 3:3, 265-282
CrossRef213
Emily J. Tsai, David A. Kass. (2009) Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacology & Therapeutics 122:3, 216-238
CrossRef214
Vallerie V. McLaughlin, David B. Badesch, Marion Delcroix, Thomas R. Fleming, Sean P. Gaine, Nazzareno Galiè, J. Simon R. Gibbs, Nick H. Kim, Ronald J. Oudiz, Andrew Peacock, Steeve Provencher, Olivier Sitbon, Victor F. Tapson, Werner Seeger. (2009) End Points and Clinical Trial Design in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 54:1, S97-S107
CrossRef215
N. J. Davie, R. T. Schermuly, N. Weissmann, F. Grimminger, H. A. Ghofrani. (2009) The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. European Journal of Clinical Investigation 39, 38-49
CrossRef216
Maria J. Ruiz-Cano, Pilar Escribano, Rafael Alonso, Juan Delgado, Patricia Carreira, Teresa Velazquez, Miguel A. Gomez Sanchez, Carlos Sáenz de la Calzada. (2009) Comparison of Baseline Characteristics and Survival Between Patients With Idiopathic and Connective Tissue Disease–related Pulmonary Arterial Hypertension. The Journal of Heart and Lung Transplantation 28:6, 621-627
CrossRef217
Daniel Wolf. (2009) Clinical practice: pulmonary hypertension in children. European Journal of Pediatrics 168:5, 515-522
CrossRef218
H Al-Ameri, R A Kloner. (2009) Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors. International Journal of Impotence Research 21:3, 149-157
CrossRef219
Robyn J. Barst, Duncan Stewart. (2009) Conventional and targeted medical therapies. Cardiology in the Young 19:S1, 28
CrossRef220
Praneet Kumar, Gary S. Francis, W. H. Wilson Tang. (2009) Phosphodiesterase 5 inhibition in heart failure: mechanisms and clinical implications. Nature Reviews Cardiology 6:5, 349-355
CrossRef221
R. Krishna Kumar, Julio Sandoval. (2009) Advanced pulmonary vascular disease: the Eisenmenger syndrome. Cardiology in the Young 19:S1, 39
CrossRef222
Vallerie V. McLaughlin, Stephen L. Archer, David B. Badesch, Robyn J. Barst, Harrison W. Farber, Jonathan R. Lindner, Michael A. Mathier, Michael D. McGoon, Myung H. Park, Robert S. Rosenson, Lewis J. Rubin, Victor F. Tapson, John Varga. (2009) ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. Journal of the American College of Cardiology 53:17, 1573-1619
CrossRef223
Saeed Abdelwhab, Mohamed Abdelwhab. (2009) Pulmonary Hypertension in Renal Failure Patients. Kidney 18:2, 68-73
CrossRef224
Peter M. Mourani, Marci K. Sontag, D. Dunbar Ivy, Steven H. Abman. (2009) Effects of Long-Term Sildenafil Treatment for Pulmonary Hypertension in Infants with Chronic Lung Disease. The Journal of Pediatrics 154:3, 379-384.e2
CrossRef225
Karen M. Olsson, Marius M. Hoeper. (2009) Novel approaches to the pharmacotherapy of pulmonary arterial hypertension. Drug Discovery Today 14:5-6, 284-290
CrossRef226
Wouter Jacobs, Anco Boonstra, J. Tim Marcus, Pieter E. Postmus, Anton Vonk-Noordegraaf. (2009) Addition of Prostanoids in Pulmonary Hypertension Deteriorating on Oral Therapy. The Journal of Heart and Lung Transplantation 28:3, 280-284
CrossRef227
T Radovits, T Bömicke, G Kökény, R Arif, S Loganathan, K Kécsán, S Korkmaz, E Barnucz, P Sandner, M Karck, G Szabó. (2009) The phosphodiesterase-5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitus. British Journal of Pharmacology 156:6, 909-919
CrossRef228
Charalambos Vlachopoulos, Nikolaos Ioakeimidis, Konstantinos Rokkas, Christodoulos Stefanadis. (2009) Cardiovascular Effects of Phosphodiesterase Type 5 Inhibitors. Journal of Sexual Medicine 6:3, 658-674
CrossRef229
Aydin Uzunpinar, Mehmet Cilingiroglu. (2009) Pulmonary arterial hypertension. Current Atherosclerosis Reports 11:2, 139-145
CrossRef230
Josef Stehlik, Matthew A. Movsesian. (2009) Combined Use of PDE5 Inhibitors and Nitrates in the Treatment of Pulmonary Arterial Hypertension in Patients With Heart Failure. Journal of Cardiac Failure 15:1, 31-34
CrossRef231
Stephen C. Mathai, Laura K. Hummers, Hunter C. Champion, Fredrick M. Wigley, Ari Zaiman, Paul M. Hassoun, Reda E. Girgis. (2009) Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease. Arthritis & Rheumatism 60:2, 569-577
CrossRef232
M. D. McGoon, G. C. Kane. (2009) Pulmonary Hypertension: Diagnosis and Management. Mayo Clinic Proceedings 84:2, 191-207
CrossRef233
S. Schafer, P. Ellinghaus, W. Janssen, F. Kramer, K. Lustig, H. Milting, R. Kast, M. Klein. (2009) Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovascular Research 82:1, 30-39
CrossRef234
M. Kuhn. (2009) Cardiac anti-remodelling effects of phosphodiesterase type 5 inhibitors: afterload-(in)dependent?. Cardiovascular Research 82:1, 4-6
CrossRef235
Motoshige Yamasaki, Keiichi Tambara, Shiori Kawasaki, Taira Yamamoto, Keita Kikuchi, Hirotaka Inaba, Atsushi Amano. (2009) Effect of Sildenafil on Pulmonary Hypertension after a Case of Residual Shunt of Ventricular Septal Defect. Japanese Journal of Cardiovascular Surgery 38:4, 252-258
CrossRef236
M. Halank. (2009) Milde symptomatische pulmonal-arterielle Hypertonie. Der Pneumologe 6:1, 35-36
CrossRef237
Jeffrey A. Feinstein. (2009) Evaluation, Risk Stratification, and Management of Pulmonary Hypertension in Patients With Congenital Heart Disease. Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual 12:1, 106-111
CrossRef238
Fusae Sawamura, Masami Kato, Kazuhisa Fujita, Takahiro Nakazawa, Anthony Beardsworth. (2009) Tadalafil, a Long-Acting Inhibitor of PDE5, Improves Pulmonary Hemodynamics and Survival Rate of Monocrotaline-Induced Pulmonary Artery Hypertension in Rats. Journal of Pharmacological Sciences 111:3, 235-243
CrossRef239
Yuan James Rao, Lei Xi. (2009) Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. Acta Pharmacologica Sinica 30:1, 1-24
CrossRef240
Michael S. Gough, R. James White. (2009) Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. Liver Transplantation 15:1, 30-36
CrossRef241
Erika B. Rosenzweig, Robyn J. Barst. (2009) Pulmonary arterial hypertension in children: A Medical Update. The Indian Journal of Pediatrics 76:1, 77-81
CrossRef242
Antonio Román Broto, Víctor Monforte Torres. (2009) Tratamiento combinado de la hipertensión arterial pulmonar. Archivos de Bronconeumología 45:1, 36-40
CrossRef243
Anna R. Hemnes, Ivan M. Robbins. (2009) Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. Liver Transplantation 15:1, 15-19
CrossRef244
Christopher J. Rhodes, Alexandra Davidson, J. Simon R. Gibbs, John Wharton, Martin R. Wilkins. (2009) Therapeutic targets in pulmonary arterial hypertension. Pharmacology & Therapeutics 121:1, 69-88
CrossRef245
Michihiko Ueno, Tomoaki Murakami, Atsuhito Takeda, Mitsuru Kubota. (2009) Efficacy of Oral Sildenafil in a Beraprost-Treated Patient With Severe Pulmonary Hypertension Secondary to Type I Glycogen Storage Disease. Circulation Journal 73:10, 1965-1968
CrossRef246
Justin S. W. Taylor, Julian P. J. Halcox. (2008) PDE5 inhibitors and pulmonary hypertension. Current Sexual Health Reports 5:4, 171-178
CrossRef247
Ravi V. Shah, Marc J. Semigran. (2008) Pulmonary hypertension secondary to left ventricular systolic dysfunction: Contemporary diagnosis and management. Current Heart Failure Reports 5:4, 226-232
CrossRef248
Gregorio Miguel Pérez-Peñate, Gabriel Juliá-Serdà, Nazario Ojeda-Betancort, Antonio García-Quintana, Juan Pulido-Duque, Aurelio Rodríguez-Pérez, Pedro Cabrera-Navarro, Miguel Angel Gómez-Sánchez. (2008) Long-term Inhaled Nitric Oxide Plus Phosphodiesterase 5 Inhibitors for Severe Pulmonary Hypertension. The Journal of Heart and Lung Transplantation 27:12, 1326-1332
CrossRef249
A.J. Becker, S. Ückert, C.G. Stief. (2008) Grundlagen der Phosphodiesterase-5- (PDE5-)Inhibitoren. Der Urologe 47:12, 1582-1587
CrossRef250
D. Carmier, S. Marchand-Adam, P. Diot, E. Diot. (2008) Atteinte respiratoire au cours du lupus érythémateux systémique. Revue des Maladies Respiratoires 25:10, 1289-1303
CrossRef251
Francisco José García Hernández, María Jesús Castillo Palma, Rocío González León, Rocío Garrido Rasco, Celia Ocaña Medina, Julio Sánchez Román. (2008) Experiencia en el tratamiento de la hipertensión arterial pulmonar con imatinib. Archivos de Bronconeumología 44:12, 689-691
CrossRef252
J. Sánchez Román, F.J. García Hernández, M.J. Castillo Palma, R. González León. (2008) Tratamiento de la hipertensión arterial pulmonar. Estrategias terapéuticas. Fármacos. Criterios de empleo. Indicaciones. Contraindicaciones. Posología. Efectos secundarios. Criterios de asociación y sustitución. Medicine - Programa de Formación Médica Continuada Acreditado 10:23, 1566-1574
CrossRef253
A Bin-Nun, M D Schreiber. (2008) Role of iNO in the modulation of pulmonary vascular resistance. Journal of Perinatology 28, S84-S92
CrossRef254
Konstantinos Dimopoulos, Georgios Giannakoulas, Stephen John Wort, Michael A Gatzoulis. (2008) Pulmonary arterial hypertension in adults with congenital heart disease: distinct differences from other causes of pulmonary arterial hypertension and management implications. Current Opinion in Cardiology 23:6, 545-554
CrossRef255
Robert Voswinckel, Frank Reichenberger, Beate Enke, Andre Kreckel, Stefanie Krick, Henning Gall, Ralph Theo Schermuly, Friedrich Grimminger, Lewis J. Rubin, Horst Olschewski, Werner Seeger, Hossein A. Ghofrani. (2008) Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulmonary Pharmacology & Therapeutics 21:5, 824-832
CrossRef256
Marco Guazzi. (2008) Alveolar Gas Diffusion Abnormalities in Heart Failure. Journal of Cardiac Failure 14:8, 695-702
CrossRef257
N. Galie, A. Manes, L. Negro, M. Palazzini, M. L. Bacchi-Reggiani, A. Branzi. (2008) A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. European Heart Journal 30:4, 394-403
CrossRef258
Konstantinos Dimopoulos, Ana Peset, Michael A. Gatzoulis. (2008) Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. International Journal of Cardiology 129:2, 163-171
CrossRef259
Michael M Lederman, Daniel Sereni, Gérald Simonneau, Norbert F Voelkel. (2008) Editorsʼ perspective and conclusions. AIDS 22:Suppl 3, S63-S67
CrossRef260
C. R. Hamilton-Craig, K. McNeil, J. Dunning, D. L. Walters, R. Slaughter, F. Kermeen. (2008) Treatment options and strategies for acute severe pulmonary embolism. Internal Medicine Journal 38:8, 657-667
CrossRef261
Kuei-Chuan Lee, Ying-Ying Yang, Ying-Wen Wang, Ming-Chih Hou, Fa-Yauh Lee, Han-Chieh Lin, Shou-Dong Lee. (2008) Acute administration of sildenafil enhances hepatic cyclic guanosine monophosphate production and reduces hepatic sinusoid resistance in cirrhotic patients. Hepatology Research???-???
CrossRef262
D. S. O’Callaghan, K. McNeil. (2008) Pulmonary hypertension and left heart disease: emerging concepts and treatment strategies. International Journal of Clinical Practice 62, 29-31
CrossRef263
Zhu JunHui, Wang XingXiang, Fu GuoSheng, Shang YunPeng, Zhang FuRong, Chen JunZhu. (2008) Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension. Respiratory Medicine 102:7, 1073-1079
CrossRef264
Robert P. Frantz, Raymond L. Benza, Barbro Kjellström, Robert C. Bourge, Robyn J. Barst, Tom D. Bennett, Michael D. McGoon. (2008) Continuous Hemodynamic Monitoring in Patients With Pulmonary Arterial Hypertension. The Journal of Heart and Lung Transplantation 27:7, 780-788
CrossRef265
Eric M. Snyder, Thomas P. Olson, Bruce D. Johnson, Robert P. Frantz. (2008) Influence of sildenafil on lung diffusion during exposure to acute hypoxia at rest and during exercise in healthy humans. European Journal of Applied Physiology 103:4, 421-430
CrossRef266
Jayan Nagendran, Vikram Gurtu, David Z. Fu, Jason R.B. Dyck, Al Haromy, David B. Ross, Ivan M. Rebeyka, Evangelos D. Michelakis. (2008) A dynamic and chamber-specific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted. The Journal of Thoracic and Cardiovascular Surgery 136:1, 168-178.e3
CrossRef267
Dermot S. O'Callaghan. (2008) Emerging treatments for pulmonary arterial hypertension. The Clinical Respiratory Journal 2:3, 132-140
CrossRef268
Oliver Distler, Frank Behrens, David Pittrow, Doerte Huscher, Christopher P. Denton, Ivan Foeldvari, Marc Humbert, Marco Matucci-Cerinic, Peter Nash, Christian F. Opitz, Lewis J. Rubin, James R. Seibold, Daniel E. Furst, . (2008) Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: A Delphi consensus study with cluster analysis. Arthritis & Rheumatism 59:6, 867-875
CrossRef269
A. Giardini, A. Balducci, S. Specchia, G. Gargiulo, M. Bonvicini, F. M. Picchio. (2008) Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. European Heart Journal 29:13, 1681-1687
CrossRef270
Riina Marjaana Spring, Silvia Ulrich, Lars C. Huber, Rudolf Speich, Marco Maggiorini, Ursula Treder, Manuel Fischler. (2008) Sildenafil for pulmonary hypertension: Dose-dependent improvement in exercise performance. Pulmonary Pharmacology & Therapeutics 21:3, 516-521
CrossRef271
N Galiè, LJ Rubin, MM Hoeper, P Jansa, H Al-Hiti, GMB Meyer, E Chiossi, A Kusic-Pajic, G Simonneau. (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. The Lancet 371:9630, 2093-2100
CrossRef272
Sebastiaan Holverda, Heleen Rietema, Harm J. Bogaard, Nico Westerhof, Pieter E. Postmus, Anco Boonstra, Anton Vonk-Noordegraaf. (2008) Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Pulmonary Pharmacology & Therapeutics 21:3, 558-564
CrossRef273
Erika B Rosenzweig, Robyn J Barst. (2008) Pulmonary arterial hypertension in children: a medical update. Current Opinion in Pediatrics 20:3, 288-293
CrossRef274
Marco Guazzi. (2008) Sildenafil and phosphodiesterase-5 inhibitors for heart failure. Current Heart Failure Reports 5:2, 110-114
CrossRef275
Renata Villela, Sai Yan Yuen, Janet E. Pope, Murray Baron, . (2008) Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment. Arthritis & Rheumatism 59:5, 706-713
CrossRef276
Raymond J. Foley. (2008) Right Ventricular Failure in the Critically Ill Patient With Pulmonary Arterial Hypertension. Clinical Pulmonary Medicine 15:3, 161-166
CrossRef277
Hsin-Hung Tsai, Ing-Jun Chen, Yi-Ching Lo. (2008) Effects of San-Huang-Xie-Xin-Tang on U46619-induced increase in pulmonary arterial blood pressure. Journal of Ethnopharmacology 117:3, 457-462
CrossRef278
S. Y. Yuen, J. E. Pope. (2008) Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. Rheumatology 47:9, 1367-1372
CrossRef279
Alice Behling, Luis E. Rohde, Fernanda C. Colombo, Livia A. Goldraich, Ricardo Stein, Nadine Clausell. (2008) Effects of 5′-Phosphodiesterase Four-Week Long Inhibition With Sildenafil in Patients With Chronic Heart Failure: A Double-Blind, Placebo-Controlled Clinical Trial. Journal of Cardiac Failure 14:3, 189-197
CrossRef280
Kelly M. Chin, Lewis J. Rubin. (2008) Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 51:16, 1527-1538
CrossRef281
Edgar Lik-Wui Tay, Michelle Koh Geok-Mui, Margaret Choong Poh-Hoon, James Yip. (2008) Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: A case series of 12 patients. International Journal of Cardiology 125:3, 416-417
CrossRef282
P. Cacoub, Z. Amoura, D. Langleben. (2008) La prise en charge thérapeutique de l’hypertension artérielle pulmonaire par les antagonistes des récepteurs de l’endothéline en 2008. La Revue de Médecine Interne 29:4, 283-289
CrossRef283
F Bellotto, M Ruscazio, G Bonanni, R Montisci, A Cutolo, C Sarais, T Setzu, A Borrini, S Iliceto. (2008) Immediate- and late-hemodynamic coronary effects of tadalafil in men with erectile dysfunction and coronary artery disease. International Journal of Impotence Research 20:2, 168-172
CrossRef284
Teresa M Attinà, Lorenzo S Malatino, Simon R Maxwell, Paul L Padfield, David J Webb. (2008) Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients. Journal of Hypertension 26:3, 501-507
CrossRef285
E. Friedrichson, P. Rehberger, J.T. Fuhrmann, F. Walz, M. Meurer, C. Pfeiffer. (2008) Rasche Abheilung von akralen Ulzera bei systemischer Sklerodermie unter Sildenafil. Der Hautarzt 59:3, 230-232
CrossRef286
J. Sánchez Román, F.J. García Hernández, M.J. Castillo Palma, C. Ocaña Medina. (2008) Diagnóstico y tratamiento de la hipertensión pulmonar. Revista Clínica Española 208:3, 142-155
CrossRef287
Nils Milman, Christopher M. Burton, Martin Iversen, Regitze Videbæk, Claus V. Jensen, Jørn Carlsen. (2008) Pulmonary Hypertension in End-stage Pulmonary Sarcoidosis: Therapeutic Effect of Sildenafil?. The Journal of Heart and Lung Transplantation 27:3, 329-334
CrossRef288
H. Klein, N. Ehlken, A. Isele, H. Wenz, F.J.F. Herth, E. Grünig. (2008) Bewegungstherapie bei pulmonaler Hypertonie. Der Pneumologe 5:2, 98-102
CrossRef289
Myung H. Park. (2008) Advances in diagnosis and treatment in patients with pulmonary arterial hypertension. Catheterization and Cardiovascular Interventions 71:2, 205-213
CrossRef290
Lewis J. Rubin. (2008) Treatment of Pulmonary Arterial Hypertension Due to Scleroderma: Challenges for the Future. Rheumatic Disease Clinics of North America 34:1, 191-197
CrossRef291
IWJM van der Horst, I Reiss, D Tibboel. (2008) Therapeutic targets in neonatal pulmonary hypertension: linking pathophysiology to clinical medicine. Expert Review of Respiratory Medicine 2:1, 85-96
CrossRef292
Yuming Zhu, Shijiang Zhang, Weiping Xie, Qingling Li, Yanjuan Zhou, Hong Wang. (2008) Iptakalim inhibited endothelin-1-induced proliferation of human pulmonary arterial smooth muscle cells through the activation of KATP channel. Vascular Pharmacology 48:2-3, 92-99
CrossRef293
Rosario Rossi, Annachiara Nuzzo, Antonella Lattanzi, Francesca Coppi, Maria Grazia Modena. (2008) Sildenafil improves endothelial function in patients with pulmonary hypertension. Pulmonary Pharmacology & Therapeutics 21:1, 172-177
CrossRef294
Mirjam E. van Albada, Rolf M.F. Berger. (2008) Pulmonary arterial hypertension in congenital cardiac disease – the need for refinement of the Evian-Venice classification. Cardiology in the Young 18:01,
CrossRef295
Lorenzo Ghiadoni, Daniele Versari, Stefano Taddei. (2008) Phosphodiesterase 5 inhibition in essential hypertension. Current Hypertension Reports 10:1, 52-57
CrossRef296
A. Aversa, C. Vitale, M. Volterrani, A. Fabbri, G. Spera, M. Fini, G. M. C. Rosano. (2008) Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabetic Medicine 25:1, 37-44
CrossRef297
Silvia Ulrich, Mark R. Nicolls, Laima Taraseviciene, Rudolf Speich, Norbert Voelkel. (2008) Increased Regulatory and Decreased CD8+ Cytotoxic T Cells in the Blood of Patients with Idiopathic Pulmonary Arterial Hypertension. Respiration 75:3, 272-280
CrossRef298
Stephen Y. Chan, Joseph Loscalzo. (2008) Pathogenic mechanisms of pulmonary arterial hypertension. Journal of Molecular and Cellular Cardiology 44:1, 14-30
CrossRef299
Mardi Gomberg-Maitland, Thenappan Thenappan, Kamran Rizvi, Sonal Chandra, David M. Meads, Stephen P. McKenna. (2008) United States Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). The Journal of Heart and Lung Transplantation 27:1, 124-130
CrossRef300
Steven H. Abman. 2008. Cor Pulmonale and Pulmonary Complications of Cardiac Disease. , 735-757.
CrossRef301
Anna K. Reed, Timothy W. Evans, Stephen J. Wort. 2008. Pulmonary Hypertension. , 783-796.
CrossRef302
D. Dunbar Ivy, Aimee K. Doran, Kelly J. Smith, George B. Mallory, Maurice Beghetti, Robyn J. Barst, Daniela Brady, Yuk Law, Donna Parker, Lori Claussen, Steven H. Abman. (2008) Short- and Long-Term Effects of Inhaled Iloprost Therapy in Children With Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 51:2, 161-169
CrossRef303
Pedro Sánchez-Aparicio, Daniel Mota-Rojas, Alejandro A. Nava-Ocampo, Maria Elena Trujillo-Ortega, Alfonso Alfaro-Rodríguez, Emilio Arch, María Alonso-Spilsbury. (2008) Effects of sildenafil on the fetal growth of guinea pigs and their ability to survive induced intrapartum asphyxia. American Journal of Obstetrics and Gynecology 198:1, 127.e1-127.e6
CrossRef304
Gary Burgess, Hans Hoogkamer, Lorraine Collings, Jasper Dingemanse. (2008) Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. European Journal of Clinical Pharmacology 64:1, 43-50
CrossRef305
R.E. Walter. (2008) Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Yearbook of Medicine 2008, 51-53
CrossRef306
Satoshi Akagi, Hiromi Matsubara, Katsumasa Miyaji, Etsuko Ikeda, Kazuhiro Dan, Naoto Tokunaga, Kenichi Hisamatsu, Mitsuru Munemasa, Yoshihisa Fujimoto, Tohru Ohe. (2008) Additional Effects of Bosentan in Patients With Idiopathic Pulmonary Arterial Hypertension Already Treated With High-Dose Epoprostenol. Circulation Journal 72:7, 1142-1146
CrossRef307
Yasuyuki KAMATA, Masahiro IWAMOTO, Seiji MINOTA. (2008) Treatment of pulmonary hypertension associated with connective tissue disease. Japanese Journal of Clinical Immunology 31:6, 424-431
CrossRef308
James A Driscoll, Murali M Chakinala. (2008) Medical therapy for pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 9:1, 65-81
CrossRef309
Katherine F Croom, Monique P Curran. (2008) Sildenafil. Drugs 68:3, 383-397
CrossRef310
Richard N. Channick, Lewis J. Rubin. 2008. Pulmonary Vasodilators in COPD. , 699-704.
CrossRef311
M. Humbert. (2007) Traitement de l’hypertension artérielle pulmonaire idiopathique et associée à la sclérodermie systémique. La Revue de Médecine Interne 28, S273-S276
CrossRef312
Pasquale J. Palumbo. (2007) Metabolic Risk Factors, Endothelial Dysfunction, and Erectile Dysfunction in Men With Diabetes. The American Journal of the Medical Sciences 334:6, 466-480
CrossRef313
J. M. Wryobeck, G. Lippo, V. McLaughlin, M. Riba, M. Rubenfire. (2007) Psychosocial Aspects of Pulmonary Hypertension: A Review. Psychosomatics 48:6, 467-475
CrossRef314
Gustavo A. Heresi, Raed A. Dweik. (2007) Pulmonary Hypertension: Evaluation and Management. Comprehensive Therapy 33:3, 150-161
CrossRef315
Anne M. Keogh, Andrew Jabbour, Robert Weintraub, Karen Brown, Chris S. Hayward, Peter S. Macdonald. (2007) Safety and Efficacy of Transition From Subcutaneous Treprostinil to Oral Sildenafil in Patients With Pulmonary Arterial Hypertension. The Journal of Heart and Lung Transplantation 26:11, 1079-1083
CrossRef316
Todd M Bull. (2007) Screening and therapy of pulmonary hypertension in systemic sclerosis. Current Opinion in Rheumatology 19:6, 598-603
CrossRef317
P Sandner, J Hütter, H Tinel, K Ziegelbauer, E Bischoff. (2007) PDE5 inhibitors beyond erectile dysfunction. International Journal of Impotence Research 19:6, 533-543
CrossRef318
Huanchen Wang, Zier Yan, Jie Geng, Stefan Kunz, Thomas Seebeck, Hengming Ke. (2007) Crystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitors. Molecular Microbiology 66:4, 1029-1038
CrossRef319
Heidi B. Kellum, Rebecca L. Stepien. (2007) Sildenafil Citrate Therapy in 22 Dogs with Pulmonary Hypertension. Journal of Veterinary Internal Medicine 21:6, 1258-1264
CrossRef320
Fadi N. Salloum, Anindita Das, Christopher S. Thomas, Chang Yin, Rakesh C. Kukreja. (2007) Adenosine A1 receptor mediates delayed cardioprotective effect of sildenafil in mouse. Journal of Molecular and Cellular Cardiology 43:5, 545-551
CrossRef321
Sheridan Henness, Fredrick M Wigley. (2007) Current drug therapy for scleroderma and secondary Raynaud??s phenomenon: evidence-based review. Current Opinion in Rheumatology 19:6, 611-618
CrossRef322
Steven R. Goldsmith. (2007) Type 5 Phosphodiesterase Inhibition in Heart Failure. Journal of the American College of Cardiology 50:22, 2145-2147
CrossRef323
Marco Guazzi, Michele Samaja, Ross Arena, Marco Vicenzi, Maurizio D. Guazzi. (2007) Long-Term Use of Sildenafil in the Therapeutic Management of Heart Failure. Journal of the American College of Cardiology 50:22, 2136-2144
CrossRef324
Jean-Brice Marteau, Nicolas Gambier, Elise Jeannesson, Gérard Siest, Sophie Visvikis-Siest. (2007) Pharmacogenomics and antihypertensive drugs: a path toward personalized medicine. Personalized Medicine 4:4, 393-412
CrossRef325
Gustavo A. Heresi, Omar A. Minai. (2007) Lupus-associated pulmonary hypertension: Long-term response to vasoactive therapy. Respiratory Medicine 101:10, 2099-2107
CrossRef326
F. Torres. (2007) Systematic review of randomised, double-blind clinical trials of oral agents conducted in patients with pulmonary arterial hypertension. International Journal of Clinical Practice 61:10, 1756-1765
CrossRef327
Fernando Grover-Páez, Geannyne Villegas Rivera, Raúl Guillén Ortíz. (2007) Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes. Diabetes Research and Clinical Practice 78:1, 136-140
CrossRef328
Robert Naeije, Sandrine Huez. (2007) Expert opinion on available options treating pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 8:14, 2247-2265
CrossRef329
Neal Benedict, Amy Seybert, Michael A. Mathier. (2007) Evidence-Based Pharmacologic Management of Pulmonary Arterial Hypertension. Clinical Therapeutics 29:10, 2134-2153
CrossRef330
Anthony J. Bella, Ling X. DeYoung, Mussa al-Numi, Gerald B. Brock. (2007) Daily Administration of Phosphodiesterase Type 5 Inhibitors for Urological and Nonurological Indications. European Urology 52:4, 990-1005
CrossRef331
Melvyn Rubenfire, Melike Bayram, Zachary Hector-Word. (2007) Pulmonary Hypertension in the Critical Care Setting: Classification, Pathophysiology, Diagnosis, and Management. Critical Care Clinics 23:4, 801-834
CrossRef332
Naveen Garg, Mukesh Kumar Sharma, Nakul Sinha. (2007) Role of oral sildenafil in severe pulmonary arterial hypertension: Clinical efficacy and dose response relationship. International Journal of Cardiology 120:3, 306-313
CrossRef333
John H. Newman, Santwana Kar, Peter Kirkpatrick. (2007) Ambrisentan. Nature Reviews Drug Discovery 6:9, 697-698
CrossRef334
Stephen John Wort. (2007) Sildenafil in Eisenmenger syndrome: Safety first. International Journal of Cardiology 120:3, 314-316
CrossRef335
S. Gaine, M. Gomberg-Maitland. (2007) What's new in pulmonary hypertension?. International Journal of Clinical Practice 61, 3-4
CrossRef336
Elaine M.C. Chau, Katherine Y.Y. Fan, W.H. Chow. (2007) Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. International Journal of Cardiology 120:3, 301-305
CrossRef337
Hiroshi Date, Kengo Fukushima Kusano, Hiromi Matsubara, Aiko Ogawa, Hideki Fujio, Katsumasa Miyaji, Megumi Okazaki, Masaomi Yamane, Shinichi Toyooka, Motoi Aoe, Yoshifumi Sano, Motohiko Hanazaki, Keiji Goto, Shingo Kasahara, Shunji Sano, Tohru Ohe. (2007) Living-Donor Lobar Lung Transplantation for Pulmonary Arterial Hypertension After Failure of Epoprostenol Therapy. Journal of the American College of Cardiology 50:6, 523-527
CrossRef338
Timothy A. McKinsey, David A. Kass. (2007) Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nature Reviews Drug Discovery 6:8, 617-635
CrossRef339
Stephan Rosenkranz. (2007) Pulmonary hypertension: current diagnosis and treatment. Clinical Research in Cardiology 96:8, 527-541
CrossRef340
Steven W. Werns. (2007) Are nitrates safe in patients who use sildenafil? Maybe*. Critical Care Medicine 35:8, 1988-1990
CrossRef341
Paul R. Forfia. (2007) Approach to patients with heart failure and pulmonary hypertension. Current Treatment Options in Cardiovascular Medicine 9:4, 302-309
CrossRef342
Indra Narang, Mark Rosenthal, Andrew Bush. (2007) Reproducibility of cardioventilatory measurements using a respiratory mass spectrometer. Respiratory Physiology & Neurobiology 157:2-3, 310-315
CrossRef343
William O Brant, Gerald B Brock, Tom F Lue, Ronald G Gerridzen, Anthony J Bella. (2007) Salvage strategies for nonresponders to phosphodiesterase-5 inhibitor treatment for erectile dysfunction in the aging male. Aging Health 3:4, 527-542
CrossRef344
C. Ballester, B. Sarriá, E. García-Granero, E. J. Morcillo, S. Lledó, J. Cortijo. (2007) Relaxation of the isolated human internal anal sphincter by sildenafil. British Journal of Surgery 94:7, 894-902
CrossRef345
Raymond Ching-Chiew Wong, Geok Mui Koh, Poh Hoon Choong, Wei Luen James Yip. (2007) Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension. International Journal of Cardiology 119:3, 400-402
CrossRef346
D. Dumitrescu, H. Freyhaus, K. Wasserman, S. Rosenkranz. (2007) Pulmonale Hypertonie. Der Pneumologe 4:4, 283-302
CrossRef347
Petros Perimenis, Konstantinos Giannitsas. (2007) Safety of sildenafil in the treatment of erectile dysfunction in patients with obstructive sleep apnoea. Expert Opinion on Drug Safety 6:4, 423-430
CrossRef348
Lucy Waite, Rajan Madhok. (2007) Pulmonary hypertension in systemic sclerosis: a review of diagnostic and therapeutic options. Future Rheumatology 2:3, 279-286
CrossRef349
Alejandro Macchia, Roberto Marchioli, RosaMaria Marfisi, Marco Scarano, Giacomo Levantesi, Luigi Tavazzi, Gianni Tognoni. (2007) A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodology. American Heart Journal 153:6, 1037-1047
CrossRef350
Vitalie Faoro, Michel Lamotte, Gael Deboeck, Adriana Pavelescu, Sandrine Huez, Hervé Guenard, Jean-Benoît Martinot, Robert Naeije. (2007) Effects of Sildenafil on Exercise Capacity in Hypoxic Normal Subjects. High Altitude Medicine & Biology 8:2, 155-163
CrossRef351
J. Suntharalingam, R.J. Hughes, K. Goldsmith, N. Doughty, P. George, M. Toshner, K.K. Sheares, J. Pepke-Zaba. (2007) Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH). Vascular Pharmacology 46:6, 449-455
CrossRef352
Antonio Aversa, Roberto Bruzziches, Cristiana Vitale, Giuseppe Marazzi, Davide Francomano, Giuseppe Barbaro, Giovanni Spera, Giuseppe MC Rosano. (2007) Chronic sildenafil in men with diabetes and erectile dysfunction. Expert Opinion on Drug Metabolism & Toxicology 3:3, 451-464
CrossRef353
Aniket Puri, Michael D McGoon, Sudhir S Kushwaha. (2007) Pulmonary arterial hypertension: current therapeutic strategies. Nature Clinical Practice Cardiovascular Medicine 4:6, 319-329
CrossRef354
Omar Ali, John Wharton, John Simon Russell Gibbs, Luke Howard, Martin Russell Wilkins. (2007) Emerging therapies for pulmonary arterial hypertension. Expert Opinion on Investigational Drugs 16:6, 803-818
CrossRef355
Pavel Jansa, Michael Aschermann, David Ambroz, Ales Linhart. (2007) Pulmonary arterial hypertension – the challenge in diagnosis and treatment. Current Medical Research and Opinion 23:s2, S3-S9
CrossRef356
Christopher P. Denton, Svetlana I. Nihtyanova. (2007) Therapy of pulmonary arterial hypertension in systemic sclerosis: An update. Current Rheumatology Reports 9:2, 158-164
CrossRef357
Horst Olschewski, M. M. Hoeper, M. M. Borst, R. Ewert, E. Grünig, F.-X. Kleber, B. Kopp, C. Opitz, F. Reichenberger, A. Schmeisser, D. Schranz, I. Schulze-Neick, H. Wilkens, J. Winkler, H. Worth. (2007) Diagnostik und Therapie der chronischen pulmonalen Hypertonie. Clinical Research in Cardiology 96:5, 301-330
CrossRef358
Raymond L. Benza, Myung H. Park, Anne Keogh, Reda E. Girgis. (2007) Management of Pulmonary Arterial Hypertension With a Focus on Combination Therapies. The Journal of Heart and Lung Transplantation 26:5, 437-446
CrossRef359
Michael A. Gatzoulis, Robyn Barst, Jeffrey Fineman, Nazzareno Galiè. (2007) Eisenmenger syndrome and pulmonary arterial hypertension in adults with congenital heart disease. Current Medical Research and Opinion 23:s2, S19-S25
CrossRef360
Isabel Otero González, Marina Blanco Aparicio, Ana Souto Alonso, Inés Raposo Sonnenfeld, Héctor Verea Hernando. (2007) Hipertensión pulmonar: eficacia clínica del sildenafilo en clases funcionales II-III. Archivos de Bronconeumología 43:5, 272-276
CrossRef361
Nazzareno Galiè, Naushad Hirani, Alessandra Manes, Serena Romanazzi, Massimiliano Palazzini, Luca Negro, Angelo Branzi. (2007) Long-term therapeutic outcomes in pulmonary arterial hypertension. Current Medical Research and Opinion 23:s2, S11-S18
CrossRef362
Yannick Allanore, Jèrôme Avouac, Julien Wipff, André Kahan. (2007) New therapeutic strategies in the management of systemic sclerosis. Expert Opinion on Pharmacotherapy 8:5, 607-615
CrossRef363
S. Rosenkranz. (2007) Pulmonal arterielle Hypertonie. Clinical Research in Cardiology Supplements 2:2, 101-119
CrossRef364
Anne V. LaRaia, Aaron B. Waxman. (2007) Pulmonary Arterial Hypertension: Evaluation and Management. Southern Medical Journal 100:4, 393-399
CrossRef365
Xing-Xiang Wang, Fu-Rong Zhang, Yun-Peng Shang, Jun-Hui Zhu, Xu-Dong Xie, Qian-Min Tao, Jian-Hua Zhu, Jun-Zhu Chen. (2007) Transplantation of Autologous Endothelial Progenitor Cells May Be Beneficial in Patients With Idiopathic Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 49:14, 1566-1571
CrossRef366
Ralf Ewert, Christian F. Opitz, Roland Wensel, Jörg Winkler, Michael Halank, Stephan B. Felix. (2007) Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Clinical Research in Cardiology 96:4, 211-217
CrossRef367
Inés Raposo-Sonnenfeld, Isabel Otero-González, Marina Blanco-Aparicio, Ángela Ferrer-Barba, Constancio Medrano-López. (2007) Tratamiento con sildenafilo y/o bosentán en niños y jóvenes con hipertensión arterial pulmonar idiopática y síndrome de Eisenmenger. Revista Española de Cardiología 60:4, 366-372
CrossRef368
Jennifer L. Snow, Steven M. Kawut. (2007) Surrogate End Points in Pulmonary Arterial Hypertension: Assessing the Response to Therapy. Clinics in Chest Medicine 28:1, 75-89
CrossRef369
Jeffrey S. Sager, Vivek N. Ahya. (2007) Surgical Therapies for Pulmonary Arterial Hypertension. Clinics in Chest Medicine 28:1, 187-202
CrossRef370
Adolfo Baloira. (2007) Futuro del tratamiento de la hipertensión pulmonar. Archivos de Bronconeumología 43:3, 131-135
CrossRef371
Shoaib Alam, Harold I. Palevsky. (2007) Standard Therapies for Pulmonary Arterial Hypertension. Clinics in Chest Medicine 28:1, 91-115
CrossRef372
Paul R. Forfia, Myung Lee, Richard S. Tunin, Mobusher Mahmud, Hunter C. Champion, David A. Kass. (2007) Acute Phosphodiesterase 5 Inhibition Mimics Hemodynamic Effects of B-Type Natriuretic Peptide and Potentiates B-Type Natriuretic Peptide Effects in Failing But Not Normal Canine Heart. Journal of the American College of Cardiology 49:10, 1079-1088
CrossRef373
S.A. van Wolferen, K. Grünberg, A. Vonk Noordegraaf. (2007) Diagnosis and management of pulmonary hypertension over the past 100 years. Respiratory Medicine 101:3, 389-398
CrossRef374
Dermot O'Callaghan, Sean P. Gaine. (2007) Combination Therapy and New Types of Agents for Pulmonary Arterial Hypertension. Clinics in Chest Medicine 28:1, 169-185
CrossRef375
Gautham Ravipati, John A. McClung, Wilbert S. Aronow, Stephen J. Peterson, William H. Frishman. (2007) Type 5 Phosphodiesterase Inhibitors in the Treatment of Erectile Dysfunction and Cardiovascular Disease. Cardiology in Review 15:2, 76-86
CrossRef376
Ana Oliveira, Daniela Ferreira, António Caiado, Susana Ferreira, Paula Ferreira, Lino Santos, Manuel Gonçalves, Teresa Shiang, Bárbara Parente, Rosas Vieira, Vasco Gama Ribeiro. (2007) Hipertensão arterial pulmonar – Experiência do Centro Hospitalar de Vila Nova de Gaia. Revista Portuguesa de Pneumologia (English Edition) 13:2, 239-254
CrossRef377
Vladimiro L. Vida, Guillermo Gaitan, Emilio Quezada, Joaquin Barnoya, Aldo R. Castañeda. (2007) Low-dose oral sildenafil for patients with pulmonary hypertension: a cost-effective solution in countries with limited resources. Cardiology in the Young 17:01, 72
CrossRef378
BKS Sastry. (2007) Pharmacologic treatment for pulmonary arterial hypertension. Current Opinion in Internal Medicine 6:1, 11-18
CrossRef379
Yoshihiro Fukumoto, Shunsuke Tawara, Hiroaki Shimokawa. (2007) Recent Progress in the Treatment of Pulmonary Arterial Hypertension: Expectation for Rho-Kinase Inhibitors. The Tohoku Journal of Experimental Medicine 211:4, 309-320
CrossRef380
Robyn J Barst. (2007) Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 8:1, 95-109
CrossRef381
Jacob M van Laar, Jan Stolk, Alan Tyndall. (2007) Scleroderma Lung. Drugs 67:7, 985-996
CrossRef382
K.L. Lewis. (2007) Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. Yearbook of Pulmonary Disease 2007, 191-196
CrossRef383
Kanako Yamamoto, Kazunori Kawaguchi, Kaheita Kakinoki, Kazuya Kitamura, Kuniaki Arai, Hiroshi Iida, Takashi Kagaya, Yoshio Sakai, Tatsuya Yamashita, Eishiro Mizukoshi, Akito Sakai, Masao Honda, Yasunari Nakamoto, Masayuki Takamura, Osamu Matsui, Shuichi Kaneko. (2007) A case of portopulmonary hypertension successfully treated by balloon-occluded retrograde transvenous obliteration and home oxygen therapy. Kanzo 48:7, 322-330
CrossRef384
E. Gabbay, A. Reed, T. J. Williams. (2007) Assessment and treatment of pulmonary arterial hypertension: an Australian perspective in 2006. Internal Medicine Journal 37:1, 38-48
CrossRef385
Konstantinos Hatzimouratidis, Dimitrios Hatzichristou. (2007) Phosphodiesterase Type 5 Inhibitors: The Day After. European Urology 51:1, 75-89
CrossRef386
David Sidebotham. 2007. Pulmonary Hypertension. , 374-382.
CrossRef387
Hiroaki Kawano, Hideyori Sengyoku, Osami Satoh, Shigetoshi Urabe, Yuji Koide, Katsusuke Yano. (2007) Marked Improvement with Sildenafil in a Patient with Idiopathic Pulmonary Arterial Hypertension Unresponsive to Beraprost and Sarpogrelate. Internal Medicine 46:12, 893-898
CrossRef388
Charles T. Klodell, Timothy E. Morey, Emilio B. Lobato, Juan M. Aranda, Edward D. Staples, Richard S. Schofield, Philip J. Hess, Tomas D. Martin, Thomas M. Beaver. (2007) Effect of Sildenafil on Pulmonary Artery Pressure, Systemic Pressure, and Nitric Oxide Utilization in Patients With Left Ventricular Assist Devices. The Annals of Thoracic Surgery 83:1, 68-71
CrossRef389
Yumiko TOYOSHIMA, Isamu KANEMOTO, Satoshi ARAI, Hiroaki TOYOSHIMA. (2007) A Case of Long-Term Sildenafil Therapy in a Young Dog with Pulmonary Hypertension. Journal of Veterinary Medical Science 69:10, 1073-1075
CrossRef390
Marius M. Hoeper, Stephen H. Lee, Robert Voswinckel, Massimiliano Palazzini, Xavier Jais, Alessandro Marinelli, Robyn J. Barst, Hossein A. Ghofrani, Zhi-Cheng Jing, Christian Opitz, Hans-Juergen Seyfarth, Michael Halank, Vallerie McLaughlin, Ronald J. Oudiz, Ralf Ewert, Heinrike Wilkens, Stefan Kluge, Hinrich-Cordt Bremer, Eva Baroke, Lewis J. Rubin. (2006) Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers. Journal of the American College of Cardiology 48:12, 2546-2552
CrossRef391
Jae Kwang Shim, Yong Seon Choi, Young Jun Oh, Dae Hee Kim, Yong Woo Hong, Young Lan Kwak. (2006) Effect of oral sildenafil citrate on intraoperative hemodynamics in patients with pulmonary hypertension undergoing valvular heart surgery. The Journal of Thoracic and Cardiovascular Surgery 132:6, 1420-1425
CrossRef392
Christopher F Barnett, Roberto F Machado. (2006) Sildenafil in the treatment of pulmonary hypertension. Vascular Health and Risk Management 2:4, 411-422
CrossRef393
Konstantinos, Hatzimouratidis. (2006) Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. Clinical Interventions in Aging 1:4, 403-414
CrossRef394
Teresa De Marco. (2006) Pulmonary Arterial Hypertension and Women. Cardiology in Review 14:6, 312-318
CrossRef395
Chandra Bomma, Hector O. Ventura, Gary Daniel, Hamang Patel. (2006) Adjunctive Sildenafil for the Treatment of Pulmonary Hypertension After Mitral Valve Replacement. Congestive Heart Failure 12:6, 347-348
CrossRef396
E. Vázquez Muñoz, J.J. Vázquez Rodríguez. (2006) Hipertensión pulmonar. Medicine - Programa de Formación Médica Continuada Acreditado 9:66, 4241-4247
CrossRef397
D. Launay. (2006) Compte rendu du symposium Pfizer : l'hypertension artérielle pulmonaire, la bête noire des maladies systémiques : de la sclérodermie systémique à la maladie de Rendu-Osler. La Revue de Médecine Interne 27:11, 899-902
CrossRef398
Maria Jose Ruiz, Pilar Escribano, Juan F. Delgado, Carmen Jiménez, Rocío Tello, M. Angel Gómez, C. Sáenz de la Calzada. (2006) Efficacy of Sildenafil as a Rescue Therapy for Patients With Severe Pulmonary Arterial Hypertension and Given Long-term Treatment With Prostanoids: 2-Year Experience. The Journal of Heart and Lung Transplantation 25:11, 1353-1357
CrossRef399
Erika B Rosenzweig. (2006) Emerging treatments for pulmonary arterial hypertension. Expert Opinion on Emerging Drugs 11:4, 609-619
CrossRef400
Roberta L. Keller, Phillip Moore, David Teitel, Samuel Hawgood, John McQuitty, Jeffrey R. Fineman. (2006) Abnormal vascular tone in infants and children with lung hypoplasia: Findings from cardiac catheterization and the response to chronic therapy. Pediatric Critical Care Medicine 7:6, 589-594
CrossRef401
Richard N. Channick, Horst Olschewski, Werner Seeger, Ted Staub, Robert Voswinckel, Lewis J. Rubin. (2006) Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension. Journal of the American College of Cardiology 48:7, 1433-1437
CrossRef402
C. Sunderkötter, G. Riemekasten. (2006) Raynaud-Phänomen in der Dermatologie. Der Hautarzt 57:10, 927-942
CrossRef403
Stephen L Archer, Evangelos D Michelakis. (2006) An evidence-based approach to the management of pulmonary arterial hypertension. Current Opinion in Internal Medicine 5:5, 453-460
CrossRef404
Makoto Sahara, Toshiyuki Takahashi, Yasushi Imai, Toshiaki Nakajima, Atsushi Yao, Toshihiro Morita, Yasunobu Hirata, Ryozo Nagai. (2006) New Insights in the Treatment Strategy for Pulmonary Arterial Hypertension. Cardiovascular Drugs and Therapy 20:5, 377-386
CrossRef405
K. Lunze, N. Gilbert, S. Mebus, O. Miera, W. Fehske, F. Uhlemann, E. G. Muhler, P. Ewert, P. E. Lange, F. Berger, I. Schulze-Neick. (2006) First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. European Journal of Clinical Investigation 36:s3, 32-38
CrossRef406
Jonathan F. Bach, Elizabeth A. Rozanski, John MacGregor, Jean M. Betkowski, John E. Rush. (2006) Retrospective Evaluation of Sildenafil Citrate as a Therapy for Pulmonary Hypertension in Dogs. Journal of Veterinary Internal Medicine 20:5, 1132-1135
CrossRef407
Sabina A Antoniu. (2006) Sildenafil for pulmonary arterial hypertension: when blue turns into white. Expert Opinion on Pharmacotherapy 7:13, 1801-1810
CrossRef408
H Padma-Nathan. (2006) Sildenafil citrate (Viagra) treatment for erectile dysfunction: an updated profile of response and effectiveness. International Journal of Impotence Research 18:5, 423-431
CrossRef409
Gregory D. Lewis, Marc J. Semigran. (2006) The emerging role for type 5 phosphodiesterase inhibition in heart failure. Current Heart Failure Reports 3:3, 123-128
CrossRef410
J. J. Oliver. (2006) Diabetic neuropathy - a further indication for phosphodiesterase type 5 inhibitors?. International Journal of Clinical Practice 60:9, 1026-1027
CrossRef411
K. Ahmadi-Simab, B. Hellmich, W. L. Gross. (2006) Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease. European Journal of Clinical Investigation 36:s3, 44-48
CrossRef412
Maria E. Campian, Maxim Hardziyenka, Martin C. Michel, Hanno L. Tan. (2006) How valid are animal models to evaluate treatments for pulmonary hypertension?. Naunyn-Schmiedeberg's Archives of Pharmacology 373:6, 391-400
CrossRef413
Hossein A. Ghofrani, Ian H. Osterloh, Friedrich Grimminger. (2006) Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nature Reviews Drug Discovery 5:8, 689-702
CrossRef414
Omar A. Minai, Alejandro C. Arroliga. (2006) Long-term Results After Addition of Sildenafil in Idiopathic PAH Patients on Bosentan. Southern Medical Journal 99:8, 880-883
CrossRef415
Ramiah Ramasubramanian, Raymond F. Johnson, John W. Downing, Beth H. Minzter, Ray L. Paschall. (2006) Hypoxemic Fetoplacental Vasoconstriction: A Graduated Response to Reduced Oxygen Conditions in the Human Placenta. Anesthesia & Analgesia 103:2, 439-442
CrossRef416
P. J. Roberts-Thomson, J. G. Walker. (2006) Scleroderma: it has been a long hard journey. Internal Medicine Journal 36:8, 519-523
CrossRef417
Chao Liu, Junmin Chen, Chao Liu. 2006. Endothelin receptor antagonists for pulmonary arterial hypertension. .
CrossRef418
K. Ahmadi-Simab, W. L. Gross. (2006) Pulmonale arterielle Hypertonie bei Kollagenosen: Klinik, Epidemiologie, Pathogenese, Diagnostik und Therapie. Zeitschrift für Rheumatologie 65:4, 297-305
CrossRef419
Josef Stehlik, Matthew A Movsesian. (2006) Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure. Expert Opinion on Investigational Drugs 15:7, 733-742
CrossRef420
Zaid Abassi, Farid Nakhoul, Eliyahu Khankin, Shimon A Reisner, Mordechai Yigla. (2006) Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective. Current Opinion in Nephrology and Hypertension 15:4, 353-360
CrossRef421
Dai Fukumura, Satoshi Kashiwagi, Rakesh K. Jain. (2006) The role of nitric oxide in tumour progression. Nature Reviews Cancer 6:7, 521-534
CrossRef422
Chao Liu, Kunshen Liu, Zhenguo Ji, Gang Liu. (2006) Treatments for pulmonary arterial hypertension. Respiratory Medicine 100:5, 765-774
CrossRef423
Christina Charles, Philip Clements, Daniel E Furst. (2006) Systemic sclerosis: hypothesis-driven treatment strategies. The Lancet 367:9523, 1683-1691
CrossRef424
Anna R Hemnes, Hunter C Champion. (2006) Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. Expert Review of Cardiovascular Therapy 4:3, 293-300
CrossRef425
Sabina A Antoniu. (2006) Sildenafil citrate for the treatment of pulmonary arterial hypertension. Expert Opinion on Pharmacotherapy 7:6, 825-828
CrossRef426
José Luis Callejas Rubio, Javier Salmerón Escobar, Jorge González-Calvín, Norberto Ortego Centeno. (2006) Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by Sildenafil. Liver Transplantation 12:4, 690-691
CrossRef427
(2006) Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. New England Journal of Medicine 354:10, 1091-1093
Full Text428
Sonja D Bartolome, Richard N Channick. (2006) Sildenafil for pulmonary arterial hypertension. Future Cardiology 2:2, 137-143
CrossRef429
Sabina A Antoniu. (2006) Non-prostanoid prostacyclin agonists for the treatment of pulmonary arterial hypertension. Expert Opinion on Investigational Drugs 15:3, 327-330
CrossRef430
Anna R. Hemnes, Hunter C. Champion. 2006. Diagnosis and Management of Secondary Pulmonary Hypertension. , 247-258.
CrossRef431
Rebecca Ireland. (2006) Is PDE5 inhibition effective in pulmonary arterial hypertension?. Nature Clinical Practice Cardiovascular Medicine 3:2, 63-63
CrossRef432
Kang Hyeon Choe. (2006) Complications of Chronic Obstructive Pulmonary Disease. Journal of the Korean Medical Association 49:4, 321
CrossRef433
M.D. Cheitlin. (2006) Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. Yearbook of Cardiology 2006, 392-393
CrossRef434
Steven H. Abman. (2006) Pulmonary hypertension in older children: New approaches and therapies. Paediatric Respiratory Reviews 7, S177-S179
CrossRef435
Jess Mandel. 2006. Treatment for Pulmonary Arterial Hypertension. , 99-118.
CrossRef436
Joyce A. Generali. (2006) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 41:1, 92-96
CrossRef437
Jennifer L. Snow, Peter Lloyd Jones, Darren B. Taichman. 2006. Pathobiologic Mechanisms of Pulmonary Arterial Hypertension. , 33-49.
CrossRef438
Roberto F. Machado, Mark T. Gladwin. 2006. Hemolytic Anemia Associated Pulmonary Hypertension. , 170-187.
CrossRef439
Laura B Kane, Elizabeth S Klings. (2006) Present and Future Treatment Strategies for Pulmonary Arterial Hypertension. Treatments in Respiratory Medicine 5:4, 271-282
CrossRef440
M PILLINGER. (2006) Sildenafil Citrate Therapy for Pulmonary Arterial HypertensionGalié N, for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group (Univ of Bologna, Italy; et al) N Engl J Med 353:2148–2157, 2005§. Yearbook of Medicine 2006, 60-62
CrossRef441
Charlotte Schubert. (2005) Viagra soothes the heart. news@nature
CrossRef442
Parthipan Kanthapillai, Toby J Lasserson, E. Haydn Walters, Parthipan Kanthapillai. 2004. Phosphodiesterase five inhibitors for pulmonary hypertension. .
CrossRef
- Letters
